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CHAPTER 1: GENERAL INTRODUCTION 
Introduction 
Swine influenza virus (SIV) continues to be endemic in the United States swine 
population.  The clinical signs most commonly exhibited during SIV infections include 
acute respiratory disease with coughing, dyspnea, fever, anorexia and weight loss, nasal 
and ocular discharge, and lethargy.
2
  Morbidity in infected herds is high (near 100%) 
while mortality is low (usually less than 1%) in the absence of concurrent infections and 
recovery usually begins 5-7 days after onset.
2
  Despite low mortality, SIV can cause 
significant production losses as infection has been estimated to add two weeks to the time 
it takes a pig to reach market weight.
5
  In addition to the economic and production losses 
due to influenza, the recent human influenza outbreak in 2009 has renewed concerns of 
the zoonotic potential of influenza viruses.   
Influenza A viruses belong to the family Orthomyxoviridae and contain negative 
sense, single-stranded RNA genomes.  The genome contains eight gene segments that 
encode for ten or eleven known proteins.
1
  Currently, 16 different HA and 9 different NA 
subtypes have been identified in many different animal species.
3
  Due to numerous 
subtypes and the segmented viral RNA genome, there is a large diversity among current 
influenza strains.  This diversity occurs by two different methods, antigenic shift and 
drift.  Antigenic shift, or genetic reassortment, occurs when two or more different 
influenza viruses co-infect the same cell and exchange gene segments during viral 
replication.  Antigenic drift refers to the accumulated mutations that occur in the RNA 
viral genome and are most often identified in the HA and NA genes.  Both antigenic shift 
and drift can result in decreased efficacy of current influenza vaccines.  For this reason, 
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human influenza vaccines must be updated yearly to include temporally relevant 
influenza strains that offer the best chance of protection against seasonal influenza.  
Swine influenza vaccines must also be updated periodically to remain efficacious against 
the evolving diversity of currently circulating SIV strains in the United States swine 
population.   
The first swine influenza virus was isolated in 1930
7
 and is referred to as classical 
H1N1.  This lineage of SIV was the predominant circulating virus in the US swine 
population until the 1997-98 influenza season when novel double and triple SIV 
reassortant viruses appeared.
5,11,12
  These reassortant strains were of the H3N2 subtype, 
but only the triple reassortant H3N2 containing genes from human, avian, and swine 
influenza viruses spread efficiently in the swine population.
9
  The triple reassortant H3N2 
continued to undergo reassortment at a rapid pace, resulting in the appearance of several 
novel subtypes, namely reassortant H1N1 and H1N2 subtypes.
9,10
  These viruses have 
undergone further reassortment with human influenza viruses, resulting in human-like 
H1N2 and H1N1 viruses in pigs.
8
  Most notably, the pandemic H1N1 virus, which 
contains genes of swine origin, appeared in humans in spring 2009 and quickly spread 
worldwide.
4
  The emergence of the pandemic H1N1 (pH1N1) influenza virus and the 
continuing shift and drift observed among SIV isolates demonstrates that the virus is 
constantly changing within the swine population, and that interspecies transmission can 
have devastating and costly consequences.   
It has been suggested that the pH1N1 outbreak should prompt proactive research 
for the development of more advanced influenza vaccines rather than the reactive 
traditional preparation of human influenza vaccines.
6
  Rappuoli et al. identified four 
3 
 
components required to develop a proactive influenza vaccine research program: 
adjuvants that increase cross-protection, conserved antigens, different vaccine platforms, 
and alternative vaccine delivery approaches.
12
  Two of these components, the alphavirus 
replicon vaccine platform and conserved influenza antigens, are evaluated in this 
dissertation.  In addition, these swine influenza vaccines were evaluated for efficacy and 
safety in swine.   
 The first paper presented in this dissertation describes the rapid development and 
efficacy of a recombinant HA subunit swine vaccine for protection against the 2009 
pH1N1 influenza virus.  This paper illustrates the speed with which a vaccine can be 
produced for an emerging disease using the alphavirus replicon technology. 
 The second paper examines the ability of an HA RP vaccine to be shed and spread 
among comingled cohorts, and whether the RP is capable of reverting to virulence in both 
host and non-host animals species.  This paper also presents results obtained from 
immunogenicity and efficacy studies that were performed evaluating the same vaccine. 
 The third paper evaluates different RP vaccines against the pH1N1 influenza 
virus.  First, an HA vaccine is evaluated against homologous pH1N1 challenge.  Second, 
an NP vaccine is evaluated against heterologous challenge in an attempt to identify a 
broadly-protective vaccine that is capable of protecting against multiple SIV subtypes.  
Dissertation Organization 
This dissertation is organized in a journal paper or manuscript format.  Chapter 1 
includes a brief introduction to the influenza virus and briefly describes the journal 
papers and format of this dissertation.  Chapter 2 provides a detailed literature review of 
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the alphavirus replicon vaccine technology utilized in the three journal papers.  Chapters 
3, 4, and 5 are manuscripts describing the research and results obtained by the primary 
research author, Ryan Vander Veen, along with the listed co-authors.  Chapter 6 
summarizes the general conclusions of the research followed by a brief 
acknowledgements section. 
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CHAPTER 2: ALPHAVIRUS REPLICON VACCINES 
A manuscript submitted to Animal Health Research Reviews 
Ryan L. Vander Veen, D.L. Hank Harris, Kurt I. Kamrud 
Abstract 
The alphavirus replicon technology has been utilized for many years to develop 
vaccines for both veterinary and human applications.  Many developments have been 
made to the replicon platform recently resulting in improved safety and efficacy of 
replicon particle vaccines.  This review provides a broad overview of the replicon 
technology and safety features of the system and reviews the current literature of replicon 
particle and replicon-based vaccines.   
Introduction  
Traditionally, veterinary vaccines have consisted of either modified live or 
inactivated preparations.  Modified live vaccines (MLV) have the possibility of reverting 
to virulence with subsequent spread among surrounding animals.
9,45
  Inactivated vaccines 
often generate insufficient cell-mediated immunity required for protection so must be 
combined with adjuvants that are able to induce the required immune response.
46,47
  Thus, 
there has been a focus on “second-generation” vaccines, some of which have already 
been licensed for commercial veterinary use.
46
   
Alphavirus replicon-based vaccines represent a viable option for next-generation 
vaccine development.  To date, alphavirus replicon-based vaccines have not been 
approved by any government regulatory agency for use in animals or humans.  
Alphavirus replicon particles (RP) are single-cycle, propagation-defective particles that 
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are not able to spread beyond the initial infected cells.   Replicon particles are produced 
by removing the alphavirus structural genes from the replicon RNA vector and replacing 
with a heterologous gene(s) of interest.  The helper genes can be provided in trans along 
with replicon RNA and co-transfected into permissible cells, resulting in the packaging of 
the replicon RNA.  Replicon particle vaccines have been evaluated in many different 
species of animals as well as humans with a proven record of safety and efficacy.  These 
vaccines are capable of inducing robust and balanced immune responses and offer many 
other advantages that ideal vaccines possess.   
Alphavirus biology 
The Alphavirus genus belongs to the Togaviridae family and contains 28 virus 
species.
21
  Alphaviruses are positive-sense, single-stranded RNA viruses with a genome 
of approximately 11.5kb in length.  The positive-sense genome contains two open 
reading frames (ORFs) and encodes four nonstructural proteins and five structural 
proteins.
64
  The 5’ ORF encodes four nonstructural proteins (nsp1-4) and the 3’ ORF 
encodes the virus structural proteins (capsid and glycoproteins (E3, E2, 6K and E1)).
57,64
  
The nonstructural proteins are translated from the positive-sense genomic RNA and 
function to transcribe full-length negative-sense RNA (Figure 1). Translation of the nsp1-
3 polyprotein is terminated by an opal stop codon located between nsp3 and nsp4; the 
polyprotein nsp1-4 is produced when translational readthrough occurs at the nsp3-4 
junction.
35
  The negative-sense RNA is a template for both additional genomic RNA as 
well as 26S subgenomic mRNA.  The 26S promoter is located between the two ORFs on 
the negative-sense RNA and is recognized by the nonstructural proteins for transcription 
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of a subgenomic mRNA, from which the structural proteins are translated.  This 26S 
mRNA is produced in 10-fold molar excess when compared to genomic RNA.
64
  The 
structural proteins are translated from the subgenomic 26S mRNA as a polyprotein that is 
subsequently co-translationally and post-translationally cleaved to release the capsid 
protein and the two mature envelope glycoproteins (E1 and E2).
29
  Foreign genes of 
interest can be inserted in the place of alphavirus structural genes in cDNA clones 
generating a self-replicating RNA (replicon) capable of expressing the foreign gene when 
introduced into cells.  The self-amplifying replicon RNA directs the translation of large 
amounts of heterologous protein in transfected cells, reaching levels as high as 15-20% of 
total cell protein.
56
  The replicon RNA can be packaged into RP by supplying the 
structural genes in trans in the form of capsid and glycoprotein helper RNAs (Figure 
2).
33,56
  When the helper and replicon RNAs are co-transfected into permissible cells, the 
replicon RNA is efficiently packaged into single-cycle, propagation-defective RP that are 
morphologically indistinguishable from native alphaviruses (authors’ unpublished 
observation).  Importantly, only the replicon RNA is packaged into RP, as the helper 
RNAs lack the packaging sequence required for encapsidation.  Therefore, the resulting 
RP are propagation-defective and are incapable of producing progeny particles or virus.   
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Figure 1. Alphavirus genome organization and replication strategy.  
 
 
Figure 2. Alphavirus replicon particle vaccine and packaging system.   
 
 
 
There are several features of alphavirus RP that make them attractive for vaccine 
development: 1) a proven record of safety; 2) high expression levels of heterologous 
genes; 3) dendritic cell tropism; 4) protective and balanced immune responses; 5) 
multivalent vaccine construction; 6) resistance to anti-vector immunity; 7) commercial 
vaccine production; and 8) differentiation of infected and vaccinated animals (DIVA). 
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Safety 
Replicon vectors have been developed from several different alphaviruses, 
including Venezuelan equine encephalitis virus (VEEV), Sindbis (SIN), and Semliki 
Forest virus (SFV).
10,41,56
  Replicon vectors lack the alphavirus structural protein genes 
but retain the nonstructural genes and the 26S subgenomic promoter.  Early production of 
RP were hampered by recombination events that resulted in the generation of replication-
competent virus (RCV)
10,57,70
; first generation helper RNAs encoded the capsid and 
glycoprotein genes on the same RNA molecule, and thus only required one 
recombination event to create RCV.
5,20,56
  The probability of this event occurring was 
greatly reduced by separating the helper RNAs onto two separate RNAs (“split helper” 
system).  Pushko et al. were able to demonstrate increased safety of the system by 
decreasing recombination events leading to the production of infectious virus when 
utilizing the split helper system.
56
  When both helper genes (capsid and glycoprotein) 
were present on a single RNA and co-electroporated into cells with replicon RNA 
expressing a heterologous gene, infectious virus was typically recovered, even to levels 
as high as 2x10
5
 PFU/ml.
56
  However, when the helper RNAs were split onto two 
separate RNA molecules, there was no recovery of infectious virus by either plaque 
assay, blind passaging, or intracerebral inoculation of mice.
57
  Similar split helper 
systems have also been developed for SIN and SFV helper RNAs resulting in no recovery 
of infectious virus.
18,63
  
The split helper system greatly reduces the occurrence of RCV, as separation of 
the helper RNAs requires two independent recombination events to occur for generation 
of RCV.
56,62
  Initially, helper RNAs were designed to contain a 26S promoter 
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downstream of the 5’ untranslated region because of the significant impact the promoter 
has on the production of high levels of subgenomic transcripts.  However, a recent study 
has demonstrated that the 26S promoter is not required for functional helper RNAs.
30
  
Removal of the 26S promoter results in helper RNAs that are not independent 
transcriptional units, and further reduces the probability of functional recombinations 
between the replicon and helper RNAs.  In the same study, a stop codon was introduced 
at the 3’ end of the capsid gene in place of the chymotrypsin-like cleavage site.30  This 
mutation negates the cleavage activity of the capsid protein, adding another safeguard 
against functional recombination.  Thus, helper RNAs lacking 26S promoters that have 
been manipulated to include a capsid stop codon have a reduced probability of functional 
recombination than the standard split helper RNA system.
30
   The introduction of the split 
helper system and subsequent modifications were significant advances in replicon 
technology that have facilitated RP vaccine evaluation in vivo without risk of reversion to 
virulence.     
Human preclinical evaluation of cytomegalovirus (CMV) and influenza RP 
vaccines has been completed with no adverse effects reported in toxicology studies.  An 
HA/NA influenza RP vaccine was administered to white rabbits four times with no toxic 
side effects and no relevant clinical parameter differences observed between RP and 
placebo vaccinated animals.
24
  Similar results were observed following evaluation of a 
candidate CMV RP vaccine in rabbits.
59
  This CMV vaccine has recently been evaluated 
in a Phase I human study where the vaccine was well tolerated with only mild to 
moderate local reactogenicity and minimal systemic reactogenicity even after three 
doses.
7
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Other studies have used the mouse model of intracranial injection to demonstrate 
the safety of RP.  Intracranial (IC) injection of VEEV RP resulted in only transient 
pathology (1-2 days) and weight loss (1 day) with a rapid return to pre-injection status.
37
  
The neurovirulence of both SIN and SFV RP expressing LacZ have also been evaluated 
following IC inoculation.  Βeta-galactosidase activity was detectable in brains for 14-28 
days, but no morbidity, neuropathology, or loss of motor skills was observed in either 
study, indicating a lack of reversion to the parental virus strains.
2,43
  A biodistribution 
study done with the same SFV RP system demonstrated that following IC injection there 
was no evidence of RP RNA co-localization to either the liver or the brain after 15 days, 
and no abnormalities were observed during histopathological examination.
50
  These 
results correlate with safety studies we have completed in pigs and mice following 
injection with a RP vaccine expressing an H3 influenza gene.  The results demonstrate a 
lack of shed and spread of RP RNA and a lack of reversion to virulence following 
vaccination (manuscript submitted).  
The current molecular features of the RP system result in safe vaccines.  
However, if in such a rare circumstance the perfect pair of recombination events did 
occur in the exact order and positions needed,
30
 the resulting RCV would theoretically be 
no more virulent than the parent strain being used as the vaccine vector.  The attenuated 
VEEV strain TC-83 (commonly used in replicon vector development and production) has 
been used extensively to vaccinate military personnel and lab workers against VEEV 
infection.
1,11
  A retrospective study of hundreds of humans who received the vaccine 
from 1976 to 1990 indicated that TC-83 vaccine caused some transient reactions, but no 
serious sequelae were reported.
53
  This strongly suggests that if multiple improbable 
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functional recombination events were to occur during RP production, the resulting 
recombinant virus would theoretically be no more virulent than the infectious parent 
strain and thus would not have serious public health consequences. 
High Expression Levels of Heterologous Genes 
Pushko et al. demonstrated that transfection of several cell lines with RP 
expressing the Lassa virus N protein resulted in expression levels of nearly 20% of total 
cell protein.
56
  Kamrud et al. engineered the VEEV replicon to allow further optimization 
of protein yield and replicon packaging efficiency.
32
  Internal ribosome entry site (IRES) 
elements were inserted into the replicon vector downstream of the 26S promoter to allow 
for cap-independent translation of heterologous genes.  In addition, random nucleotide 
sequences of varying lengths were inserted between the 26S promoter and the IRES 
element.  When compared to null replicons (no IRES) the spacer-IRES replicons 
expressed protein in some instances at >50 fold increases.
32
  Thus, by varying the length 
of the spacer sequences used in conjunction with IRES elements, replicons expressing the 
highest levels of heterologous genes or resulting in the highest RP yield can be readily 
identified for vaccine evaluation.    
Dendritic Cell Tropism 
A robust immune response is dependent on accurate and rapid presentation of the 
antigen to immune effector cells.  Dendritic cells (DC) are considered professional 
antigen presenting cells so vaccines that target these cells should induce robust and 
balanced immune responses.  Inoculation of mice with VEEV RP revealed Langerhans 
cells (DC located in the skin) as the initial cell set to be infected.
44
  In humans, VEEV RP 
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have a selective human myeloid DC tropism and these DC retain the capacity to acquire 
the mature phenotype upon migration to the local draining lymph node.
52
  SFV has also 
been shown to infect Langerhans cells and subsequently migrate to the local lymph 
node.
28
  A single amino acid substitution in the E2 glycoprotein of the SIN replicon 
vector significantly increased the affinity of the particle for human DC, resulting in an 
increase of major histocompatibility complex (MHC) class II molecules, CD86, and IFN-
γ secreting cells.19  This natural or enhanced DC tropism of alphavirus RP results in a 
balanced and protective immune response following RP vaccination. 
Protective Immunity 
 The alphavirus replicon system has been used to develop efficacious RP vaccines 
for both human and veterinary applications.  Influenza RP vaccines have been evaluated 
in chickens, pigs, and humans.  Complete protection against lethal H5N1 avian influenza 
challenge was demonstrated in 2 week old chickens that received a single dose of RP 
vaccine expressing the homologous HA gene.
61
  Recent reports also demonstrate that 
protective HI responses are elicited in young pigs following HA RP vaccination.
8,17
  
Following homologous challenge, there was a significant decrease in nasal shedding, 
viral load, rectal temperatures, and pulmonary pathology in HA RP vaccinated animals 
compared to placebo controls.
8
  The alphavirus replicon system was also used to rapidly 
produce a recombinant HA protein vaccine in response to the pandemic H1N1 influenza 
outbreak in 2009 with similar protection observed following homologous challenge.
69
  
Other influenza gene candidates have also been evaluated in the RP system including 
neuraminidase (NA) and nucleoprotein (NP) with varying results.
8,24,66
  Preclinical 
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evaluation of HA and NA RP vaccines have been completed for human trials with no 
adverse effects observed following toxicology and safety testing, and robust humoral and 
cellular responses were elicited in mice, rabbits, and rhesus macaques.
24
  In addition to 
evaluation as influenza vaccine candidates, RP not expressing any heterologous genes 
(null RP) are able to act as adjuvants and enhance the immunogenicity and efficacy of a 
trivalent inactivated influenza vaccine in rhesus macaques.
12
   
  In addition to influenza, replicon particle vaccines have also been evaluated 
against several other animal diseases of veterinary importance.  Balasuriya et al. used 
VEEV RP expressing the GL and M proteins of equine arteritis virus (EAV) and 
demonstrated that these two major envelope proteins are necessary as a heterodimer for 
the induction of EAV neutralizing antibodies in mice.
4
  Further, only horses vaccinated 
with the GL/M RP vaccine were protected against virulent challenge while horses 
receiving RP expressing only the GL or M monomers were not protected from EAV.
3
  
Similar research has been completed evaluating a related Arterivirus, porcine 
reproductive and respiratory syndrome virus (PRRSV), where the GP5/M heterodimer 
has also been shown to be important for neutralizing antibody induction.
25-27
  Replicon 
particle vaccines expressing the PRRSV GP5/M heterodimer have been evaluated in 
swine with a reduction in viremia observed post-challenge.
48,49
  A recent study evaluated 
RP vaccines that encoded either the glycoproteins of Hendra or Nipah viruses,
15
 diseases 
of both veterinary and public health importance.  These vaccines were able to induce 
cross-reactive neutralizing antibodies to both viruses, suggesting that a single vaccine 
against both viruses may be possible.
15
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  In addition to alphavirus-based RP vaccines, alphavirus vectors can be designed 
to launch a self-replicating replicon RNA from a DNA plasmid in vivo.  Replicon DNA 
vaccines have been developed for SIN, SFV, and VEEV.
6,16,36,42
  The first step of 
expression involves RNA polymerase II-initiated transcription of replicon RNA from 
plasmid DNA in the transfected cells.  Currently, the CMV immediate-early promoter is 
most frequently used.
42
  The second step of expression occurs when the replicon RNA 
enters the cytoplasm and the heterologous gene of interest is amplified from the native 
alphavirus 26S subgenomic RNA promoter.  Previous SFV- and SIN-based replicon 
DNA vaccines have been shown to be immunogenic in small animal models.
6,22
  A 
VEEV replicon-based DNA plasmid consistently expressed 3- to 15-fold more protein in 
vitro and increased humoral responses by several orders of magnitude over a 
conventional DNA vaccine.
42
   As the transcribed replicon RNA is self-amplifying, 
increases in cellular and humoral responses were also observed when 100-fold lower 
doses of VEEV DNA was used compared to conventional DNA.  Additionally, when the 
VEEV DNA vaccine was used as a prime and VEEV RP expressing the same 
heterologous gene was given as the boost dose, both humoral and cellular immunity were 
increased significantly compared to VEEV DNA alone.
42
   
 Similar replicon-based DNA vaccines have recently been evaluated in mice and 
pigs.  A SFV replicon-based DNA vaccine has been produced expressing the E2 
glycoprotein of classical swine fever virus (CSFV).  Pigs vaccinated with this DNA 
vaccine elicited low levels of neutralizing antibodies one week post-booster vaccination 
but exhibited decreased clinical symptoms and reduced viremia following homologous 
challenge when compared to control pigs.
40
  When evaluated in a mouse model, this 
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vaccine elicited a specific lymphoproliferative response and an increase in IFN-γ and IL-
4 CSFV-specific secretion.
73
  When the CSFV DNA vaccine was used in a prime/boost 
regimen with a recombinant adenovirus expressing the homologous E2 glycoprotein a 
significant increase in pre-challenge neutralizing antibody titers was observed with 
subsequent protection against heterologous CSFV challenge.
72
  A SFV replicon-based 
DNA vaccine expressing the 1BCD gene of swine vesicular disease virus has also been 
shown to elicit neutralizing antibodies and lymphocyte proliferation in both guinea pigs 
and swine.
65
  A SIN virus replicon-based DNA vaccine encoding the rabies virus 
glycoprotein G induced higher levels of humoral and cell-mediated immunity in mice 
than the conventional rabies DNA vaccine and comparable to the inactivated commercial 
rabies vaccine.
60
  All of the replicon DNA and inactivated virus vaccinated mice were 
completely protected against lethal challenge while some mice receiving the conventional 
DNA vaccine did not survive.
60
  All of these results indicate that the alphavirus replicon 
technology is flexible and that replicon RNA can be delivered to the host by several 
different methods. Also, replicon technology can be used in conjunction with other 
recombinant systems to produce more efficacious vaccine regimens.  
Multivalent Vaccines 
One of the advantages of the alphavirus replicon system is that the vector can be 
genetically modified to express several different genes either from the same or different 
pathogens.  This can be accomplished via several methods, but the most common method 
is insertion of additional 26S promoter sites downstream of the non-structural genes.  
However, not all proteins are expressed at equimolar levels in this design and can depend 
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on the number of genes or gene position in the replicon, so each replicon must be 
empirically evaluated to determine optimum protein expression.
58
  Mice that received RP 
vaccines expressing different combinations of pp65, IE1, and gB proteins under control 
of three different 26S promoters developed high titers of neutralizing antibody and 
antigen-specific T-cell responses against CMV.
58
  Balasuriya et al. produced an RP 
vaccine co-expressing the GL/M heterodimer that was required for protection against 
EAV.
3
  Replicon particle vaccines expressing genes from two different pathogens are 
also able to induce protection against subsequent challenge.  An RP vaccine co-
expressing the glycoprotein genes of both Ebola and Lassa viruses protected guinea pigs 
from challenge with both viruses.
55
  The results obtained were the same as those achieved 
with RP vaccines expressing only one of the viral glycoproteins, indicating that 
protective immune responses can be induced against multiple and individual vaccine 
antigens at similar levels.  In other studies the authors have simply mixed different 
monovalent RP vaccines together prior to injection rather than producing the vaccine 
using a bivalent approach with additional 26S promoters.
23,38
  Similar to the previous 
results, a specific immune response was elicited in mice to each individual RP antigen 
including Marburg virus, anthrax, and botulinum neurtotoxin, and protection was 
demonstrated following challenge with Bacillus anthracis and botulinum neurotoxin A 
and C.
38
  The level of protection against B. anthracis induced by this multivalent vaccine 
formulation was similar to the protection demonstrated by vaccination with a monovalent 
anthrax RP vaccine.
39
   Hooper et al combined individual RP expressing four different 
smallpox virus antigens and demonstrated protection from lethal monkeypox virus 
challenge in cynomolgus macaques.
23
 Taken together, all of these results indicate that 
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multivalent RP vaccines, regardless of the method of production, are able to induce 
balanced antigen-specific immune responses and can protect against multi-agent 
challenge.  These results may be important for decreasing the number of injections 
required for protection against several diseases or serotypes of a single disease and also 
for decreasing the cost of RP vaccine production. 
Resistance to Antivector Immunity 
As the alphavirus structural genes are not packaged and thus not expressed 
following vaccination, antivector immune responses are minimal.  This lack of antivector 
immunity allows for multiple vaccinations of the same individual with either the same RP 
vaccine or different RP vaccines against multiple pathogens.  Pushko et al. first 
demonstrated that RP could be used for sequential immunization by vaccinating mice 
with two doses of RP expressing the N protein of Lassa virus and then sequentially 
vaccinating the same mice with two doses of HA RP.
56
  These mice developed positive 
serum antibody responses against both antigens.  Additionally, vaccinated mice were 
protected against influenza challenge, indicating that the Lassa N immune response did 
not interfere with subsequent influenza vaccination and the influenza-specific immune 
response.  These same results have been achieved following vaccination with RP 
expressing the HA protein from two different subtypes of influenza (authors’ unpublished 
results).  Ferrets were first immunized with an H3 RP vaccine and subsequently protected 
against homologous H3N2 influenza challenge.  These protected ferrets (pre-immunized) 
were then vaccinated with H1 RP along with a group of naïve (non-H3 RP vaccinated) 
animals.  Both the pre-immunized and naïve ferrets that received the H1 RP vaccine 
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developed equivalent H1N1 hemagglutination inhibition (HI) serum antibody titers. 
These studies confirm that RP vaccines can be used sequentially without an inhibitory 
effect on vaccine efficacy.    Other recombinant vaccines are often hindered by antivector 
immunity and it has been suggested that recombinant adenovirus vaccination regimens 
should include two heterologous vectors to avoid antivector immunity.
67
   
Commercial Vaccine Production 
Many diseases that have not yet had efficacious vaccines developed against them 
are in the NIH Risk Group 3 (ie. highly pathogenic avian influenza H5N1 and human 
immunodeficiency virus (HIV) types 1 and 2) or on the APHIS/CDC Select Agent List 
(ie. Botulinum neurotoxins, Ebola and Marburg viruses, B. anthracis, Hendra and Nipah 
viruses, foot-and-mouth disease virus (FMDV), and CSFV).  Thus, all of these pathogens 
require either BSL3 or BSL4 production facilities for traditional vaccine production.   
This requirement has almost certainly been an impediment in the development of some of 
these vaccines.  In addition, the alphavirus VEEV is also listed as a select agent, except 
for the TC-83 attenuated vaccine strain.  Thus, the TC-83 infectious clone can be utilized 
in the replicon system with the protective genes of the aforementioned select agents at 
low biocontainment levels for research and production.  Since replicon-based vaccine 
production does not require growth of the pathogenic organism, select agent replicon-
based vaccine development and production can occur in low biocontainment production 
facilities with no special biosecurity required.  The capability to produce select agent 
vaccines in such production facilities is a huge advantage of the replicon system and has 
aided the development of these crucial vaccines for both humans and animals.  The 
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attenuating determinants of TC-83 virus attenuation have been well defined.
34,35
  Because 
of the attenuated safety profile of TC-83 it has been recently developed as a replicon 
vector.
8,17,23,31
  A recent study compared a TC-83-based RP vaccine against a different RP 
vaccine (V3014-based, vaccine produced in BSL3 facilities) in pigs.  Both RP vaccines 
expressing H3N2 HA were able to elicit the same antibody response in pigs 
demonstrating that there is no difference in immunogenicity between RP vaccines 
produced using these two VEEV replicons.
17
 
 Another advantage of RP vaccines is that many different cell lines are permissive 
to alphavirus infection allowing a variety of different cells to be evaluated for maximum 
yields.  Vero and baby hamster kidney cells are most commonly used for RP production, 
but chinese hamster ovary (CHO), primary chicken (CEF) and duck (DEF) embryo 
fibroblasts, 293, and 293T cell lines have also been utilized for RP production (authors’ 
unpublished results).
56
  This long list of cells is in contrast to pathogenic virus growth 
which can usually only occur optimally in one cell line.  As in traditional vaccine 
production, these cells can be grown in large quantities using large-scale bioreactor 
microcarrier or suspension systems allowing efficient scale-up possibilities for RP 
production.  There is also a report of stably transfected cell lines that have been 
developed to constitutively express the helper RNAs needed for RP production.
54
  Similar 
to the split helper RNA system described above, only cell lines containing the structural 
protein genes on separate RNAs resulted in no recovery of RCV.
54
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DIVA Capability 
One of the attributes of a good next-generation vaccine should be the capability to 
distinguish infected from vaccinated animals (DIVA).  The DIVA concept relies on the 
principle that a vaccinated animal will have a different immune response than an animal 
that is infected with the wild-type pathogen and that this immune response is readily 
detectable by some immunoassay.  These DIVA vaccines become increasingly important 
when considering diseases that are not currently present in disease-free status countries 
(ie. FMDV and CSFV) or for disease eradication and intense surveillance programs.  In 
the case of FMDV, the current control policy has been primarily one of slaughtering the 
infected and contact animals.
68
  This policy could have a huge detrimental impact on 
domestic livestock production and potential export ramifications.  Following the 2001 
FMDV outbreak in the UK there has been a growing demand for FMDV vaccination 
following an outbreak in order to reduce the large-scale slaughter of animals for control 
of the virus.
68
  Current FMDV vaccine research is focused on development of DIVA 
vaccines expressing the capsid proteins, including FMDV replicon-based vaccine 
research (authors’ unpublished results).46,71   
Vaccines that have DIVA capabilities are also important for the control and 
eventual eradication of current endemic infectious diseases.  Porcine reproductive and 
respiratory syndrome virus (PRRSV) is endemic to the United States swine population 
and continues to have a huge economic impact.
51
  Current diagnostic assays for PRRSV 
target antibodies directed towards the nucleocapsid (N) protein.  Antibodies to the N 
protein have been shown to be non-neutralizing,
14
 and a protective vaccine need not 
include this protein to be efficacious.  Thus, RP vaccines expressing any combination of 
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PRRSV structural glycoproteins would therefore be able to differentiate vaccinated from 
naturally infected animals.  Similarly, a current ELISA for detecting influenza is based on 
NP antibody detection.
13
  Replicon particle vaccines expressing only the HA protein 
would therefore not induce a detectable immune response when used in conjunction with 
this diagnostic assay.    Therefore, alphavirus-based vaccines offer DIVA capabilities that 
can be important in different disease situations. 
Conclusions 
  Research into the potential of alphavirus replicon-based vaccines has been 
ongoing for more than 20 years.  Significant advancements have been made since these 
vectors were first used for the expression of heterologous genes.  Improvements in both 
safety and the replicon vector design have significantly advanced the field of replicon-
based vaccines.  Both RP and replicon DNA vaccines have demonstrated robust and 
balanced immune responses with subsequent protection against a variety of diseases that 
have implications for both veterinary and human health.  Thus, the alphavirus replicon 
technology offers great potential for the next generation of animal and human vaccines. 
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Abstract 
Recombinant hemagglutinin (HA) protein from a pandemic H1N1 influenza strain 
was produced using an alphavirus replicon expression system. The recombinant HA 
vaccine was produced more rapidly than traditional vaccines, and was evaluated as a 
swine vaccine candidate at different doses in a challenge model utilizing the homologous 
influenza A/California/04/2009 (H1N1) strain. Vaccinated animals showed significantly 
higher specific antibody response, reduced lung lesions and viral shedding, and higher 
average daily gain when compared to non-vaccinated control animals. These data 
demonstrate that the swine vaccine candidate was efficacious at all of the evaluated 
doses. 
Introduction 
The recent outbreak of pandemic H1N1 (pH1N1) in the global human population 
highlights the zoonotic potential of influenza viruses. The current pH1N1 virus has been 
shown to contain genes of swine origin.
4
   Even before the current pandemic, numerous 
cases of zoonotic transmission of swine influenza viruses to humans have been 
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identified.   A review of the literature in 2006 identified 37 civilian cases and 13 military 
cases of human influenza associated with swine influenza strains, spanning from 1958-
2005.
12
  Fourteen percent of these cases were documented as fatal.  A more recent study 
reviewed reported cases of triple-reassortant swine influenza subtype H1 in humans from 
2005-February 2009.
17
  They found 11 sporadic cases, and all 11 patients recovered after 
showing clinical influenza symptoms.  Nine of these 11 patients had known exposure to 
pigs, most of which were ill, either at agricultural fairs or at hog farms.  These results 
mirror studies showing increased antibody titers to swine influenza viruses among hog 
farm workers and family members.
5,13
  These studies provide evidence that human and 
swine interaction can result in the creation of pandemic influenza viruses, and thus the 
need for efficacious swine influenza vaccines.  Pandemic H1N1 vaccination can reduce 
clinical disease in pigs, and may reduce transmission among the swine population and 
decrease the zoonotic potential. 
Many vaccines have been evaluated using alphavirus replicon technology.
14
  In 
this study, the alphavirus replicon is derived from the TC-83 strain of the alphavirus 
Venezuelan equine encephalitis virus (VEEV).  In a previous study, a VEEV replicon 
vaccine expressing the HA gene from a human H5N1 isolate protected chickens from 
lethal challenge.
16
  Recently, our group became the first to evaluate VEEV replicon 
particle vaccines in swine.
3
  However, no studies have been published using replicon-
expressed recombinant proteins as vaccine candidates for swine.  The objective of this 
study was to evaluate replicon-expressed recombinant pH1N1 HA protein as a swine 
vaccine in a vaccination-challenge model.  
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Materials and Methods 
Pandemic H1N1 HA replicon subunit vaccine production 
The Influenza A/California/04/2009 hemagglutinin (HA) nucleotide sequence was 
retrieved from the Global Initiative on Sharing Avian Influenza Data (GISAID) database. 
The gene was synthesized by a commercial company (DNA2.0, Menlo Park, CA, USA) 
with unique AscI and PacI restriction sites engineered at the 5’ and 3’ ends, 
respectively.  The HA gene was cloned into the AscI/PacI sites of the pVEK (TC-83) 
replicon vector
7
 and an optimized construct was selected as previously described.
9
  The 
HA gene was then sequenced to ensure the proper sequence was maintained throughout 
the cloning process.  RNA transcripts were produced in vitro as previously 
described.
9
  Replicon RNA was mixed with Vero cells in electroporation cuvettes and 
pulsed.  Cells were incubated overnight and then lysed using RIPA buffer (Pierce, 
Rockford, IL, USA).  Resulting lysate was tested for protein expression by Western blot 
and HA protein concentration was determined by a pH1N1 HA-specific ELISA.   Lysate 
was diluted to the specified HA concentration and vaccine was adjuvanted with 
Emulsigen-D (MVP Technologies, Omaha, NE, USA). 
 Western blot analysis 
Vero cell lysate containing recombinant HA protein was separated by running on 
a 12% SDS-PAGE gel (Invitrogen, Carlsbad, CA, USA) and was then transferred to 
a PVDF membrane (Invitrogen, Carlsbad, CA).  The  ladder used was the SeeBlue 
Plus2 Pre-Stained Standard (Invitrogen, Carlsbad, CA, USA). After transfer, membrane 
was blocked with 5% non-fat dry milk at room temperature.  Membrane was incubated 
with polyclonal anti-H1N1 antibody for two hours, washed three times, followed by 
40 
 
incubation with goat anti-swine IgG horseradish peroxidase conjugate (ImmunoJackson 
Research Laboratories, Inc, West Grove, PA, USA) for one hour, and washed three 
times.  Detection was performed using TMB substrate (KPL, Gaithersburg, MD, USA). 
Direct antigen capture ELISA 
Unknown samples, negative controls,  and purified pandemic H1 protein (Protein 
Sciences, Meriden, CT, USA) were directly captured to NUNC Maxisorp (Rochester, 
NY, USA) 96-well microplates by diluting with capture buffer (50 mM 
Carbonate/Bicarbonate, pH 9.6) and incubated overnight at 4°C (100 µl/well).  The 
microplates were washed four times with wash buffer (20 mM Phosphate Buffered 
Saline, 0.05% Tween-20, pH 7.2).  The plates were blocked with 1.25% non-fat dry milk 
in capture buffer for 1 hour at 37°C (200 µl/well).  After four washes, polyclonal anti-
H1N1antibody was added to wells (100 µl) and incubated for 1 hour at 37°C (diluted 
1/500 in wash buffer containing 1.25% NFDM).  Following four washes, goat ant-pig 
IgG-HRP labeled (Jackson ImmunoResearch, West Grove, PA, USA) was added to the 
wells (100 µl) and incubated for 1 hour at 37°C (diluted 1/2000 in was buffer containing 
1.25% NFDM).  Four final washes were performed prior to the addition of 100 µl of 
TMB substrate (KPL, Gaithersburg, MD, USA) and incubation at 37°C for 20 
minutes.  Absorbance values were measured at 620 nm and a standard curve was plotted 
with the purified pandemic H1 protein.  Linear regression analysis of the standard curve 
was used to calculate the pandemic H1 concentrations in the unknowns. 
Animal study 
Pigs free of swine influenza virus (SIV) and porcine reproductive and respiratory 
syndrome virus (PRRSV) were obtained at three weeks of age.  Pigs were randomized 
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and separated into 4 groups of 5 pigs each (Table 1).  Prior to vaccination, serum was 
collected and tested by the homologous hemagglutination inhibition (HI) assay against 
the pH1N1 A/California/04/2009 influenza strain to confirm negative antibody 
status.  Sera were collected throughout the study and tested by this same HI assay to 
monitor seroconversion post-vaccination.  A prime/boost vaccination schedule was 
followed.  The first dose of vaccine was given to pigs at approximately 4 weeks of age on 
day 0.  On day 21 pigs received booster vaccination, with challenge on day 47 and 
necropsy on day 52.  Pigs received either phosphate buffered saline (PBS) (Placebo, 
Group 1) or different concentrations of pandemic H1 HA recombinant protein (Groups 2-
4, Table 1).  Pigs were challenged intratracheally with virulent A/California/04/2009 
influenza virus (CDC# 2009712047) at a dose of 2x10
5
 TCID50.  Nasal swabs were 
collected daily for live virus isolation beginning on day of challenge and continuing until 
study completion 5 days post-challenge.  Pigs were weighed immediately before 
challenge and again at necropsy for determination of average daily gain (ADG).  At 
necropsy, gross lung lesion consolidation was determined by a board-certified 
pathologist.  Lung tissue was fixed in formalin for SIV immunohistochemistry (IHC) and 
histopathological analysis.  Bronchoalveolar lavage fluid (BALF) was collected from 
lungs for live virus isolation.  This animal study was approved by the Iowa State 
University Institutional Animal Care and Use Committee. 
Hemagglutination inhibition (HI) assay 
Antibodies to influenza virus were measured by HI assay run by the University of 
Minnesota Veterinary Diagnostic Laboratory following standard laboratory protocol. 
Briefly, sera were treated with receptor-destroying enzyme, heat inactivated, adsorbed 
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with 20% turkey erythrocytes, and centrifuged. Supernatants were then serially diluted in 
V-shaped well microtiter plates with an equal volume containing 4-8 agglutinating units 
of A/California/04/2009 virus and plates were incubated at room temperature before 
addition of 0.5% turkey erythrocytes.  Titer was defined as the reciprocal of the maximal 
dilution at which hemagglutination was inhibited. 
Gross lung lesion scoring, histopathology, and SIV immunohistochemistry 
A single board-certified veterinary pathologist who was blinded to group 
treatments, performed gross lung scoring, histopathological analysis, and SIV 
Immunohistochemistry (IHC) analysis.  At necropsy, each lung lobe affected by 
pneumonia was visually estimated, and a total percentage for the entire lung was 
calculated based on weighted proportions of each lobe to the total lung volume.
6
  Tissue 
samples from the trachea and all lung lobes were collected and fixed in 10% 
formalin.  Tissues were routinely processed and stained with hematoxylin and 
eosin.  Lung samples were scored according to the method used by Vincent et al.
20
 Swine 
influenza virus IHC was done according to the method described by Vincent et al.
21
  All 
tissue preparation and staining was done by the Iowa State University Veterinary 
Diagnostic Laboratory. 
Live virus isolation 
Live virus titers were determined from nasal swabs and live virus isolation 
performed on BALF samples.  Briefly, nasal swabs and BALF samples were thawed and 
centrifuged to remove cellular debris.  The resulting supernatant was diluted 10-fold in 96 
well plates in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Carlsbad, CA, 
USA) containing 1% antibiotic-antimycotic (Gibco, Carlsbad, CA, USA) and 1% L-
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glutamine (Mediatech, Manassas, VA, USA).  After dilutions were made, 100µl was 
transferred from each well into respective wells of a 96 well plate containing a monolayer 
of swine testicle (ST) cells.  Plates were incubated at 37°C until no further CPE was 
observed, typically 3-5 days.  Wells displaying CPE were considered positive, and titers 
were calculated using the TCID50/ml method of Reed-Meunch.
15
 
Statistical analysis 
Single factor analysis of variance (ANOVA) was used to analyze homologous HI 
titers, macroscopic and histopathological lung scores, IHC and BALF results, log10 
transformed nasal swab viral titers, and ADG (JMP 8.0.1, SAS Institute Inc., Cary, NC, 
USA).  Statistical significance was set at p < 0.05. 
 Results 
Vaccine preparation 
The pH1N1 HA gene was inserted into the alphavirus replicon platform and 
nucleotide sequencing confirmed the correct HA gene sequence had been maintained 
throughout the cloning process.  Western blotting performed on protein lysate confirmed 
expression of the pandemic HA protein at all the varying HA doses (Figure 1) used in 
vaccine preparation for the animal study. The HA concentration was determined by 
pH1N1 HA ELISA and diluted to the specified HA concentration (Table 1).   
 Antibody titers     
Post-vaccination sera were tested for specific antibody response by the 
homologous HI assay.  Hemagglutination inhibition titers were not seen in vaccinated 
pigs after one dose, but were all positive (≥1:40), except for a single pig in Group 2, at 7 
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and 14 days post-boost vaccination (data not shown).  On the day of challenge, 
homologous HI titers were significantly higher in groups 2-4 when compared to group 1 
(Table 2).   
Pathological evaluation 
At necropsy, lungs exhibited macroscopic dark purplish-red consolidated lesions 
located mainly in the cranioventral lobes.  Lungs taken from groups 2-4 exhibited 
significantly lower lesion scores and consolidation than pigs in group 1 (Table 2).  There 
was also a significant reduction in pathological scores in all HA vaccinated groups 
compared to the placebo vaccinated group (Table 2).  The lung sections taken from 
placebo vaccinated group 1 pigs had approximately 50% of the airways affected by 
bronchiolar epithelial disruption and peribronchiolar lymphocytic cuffing.  The HA 
vaccinated groups 2-4 demonstrated only occasional affected airways with light 
cuffing.  Swine influenza virus IHC demonstrated that all five lungs taken from placebo 
vaccinated group 1 pigs were positive for influenza antigen, while only two pigs in total 
from the HA vaccinated groups 2-4 were positive.  Additionally, there were positive 
trachea IHC samples in all groups (data not shown), but no significant differences were 
observed between HA vaccinated and placebo vaccinated groups.  Positive trachea IHC 
results correlate with what was previously reported on pathogenesis of pandemic H1N1 
in ferrets.
11
    
Average daily gain 
Groups 3 and 4 exhibited significantly higher ADG over the five day period 
following challenge than did group 1 (Table 2).  Group 2 did exhibit higher ADG but was 
not significantly higher than group 1 (p=0.08).   
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Virus isolation 
No live influenza virus was detected at one day post-challenge from any nasal 
swabs (Table 3).  On day 2 post challenge live influenza virus was detected in groups 1, 
3, and 4, although there were no significant differences between group mean viral 
titers.  On day 3 post-challenge groups 2 and 4 had significantly lower titers than did 
group 1.  On both days 4 and 5 groups 2-4 all exhibited lower titers than group 1.  No live 
virus was detected in nasal swabs from any pigs in group 2 for the duration of the 
challenge period.  Similarly, there was a significant reduction in the number of positive 
BALF samples between groups (Table 3).  By 5 days post- challenge, only a total of three 
HA vaccinated pigs had detectable live virus in BALF samples, while all five pigs in the 
placebo vaccinated group had detectable live virus. 
 Discussion 
The recent outbreak of pH1N1 in the human population has highlighted the 
zoonotic potential of influenza viruses.  Even before the current pandemic, there were 
many reported cases of swine to human transmission of influenza.  As such, part of 
controlling this zoonotic threat is vaccination of swine against swine influenza viruses 
(SIV).  In this study, we demonstrate how rapidly an efficacious swine influenza vaccine 
based on the alphavirus replicon expression system can be produced in response to an 
outbreak of a pandemic zoonotic strain. 
This study demonstrated the quickness and flexibility with which a vaccine can be 
produced using the alphavirus replicon expression system.  It took less than two months 
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from the time the pandemic HA sequence was retrieved from GISAID database until pigs 
were administered the first vaccine dose.  Traditional methods for producing influenza 
vaccines take much longer and are dependent on viral replication in embryonated eggs or 
on tissue culture cells with subsequent inactivation.  In the face of an influenza epidemic, 
a quick turnaround is important in preventing further transmission and decreasing the 
zoonotic potential.  The alphavirus replicon platform allows for rapid insertion of any 
influenza HA (or other) gene, making it an attractive influenza vaccine technology due to 
constant antigenic shift and drift among influenza viruses.                     
This is the first report of immunization of swine with a recombinant protein 
produced via an alphavirus replicon expression system.  Replicon particle (RP) vaccines 
produced with this system have recently been utilized to induce protection against 
SIV.
1,3
  The first proof of concept study demonstrated that a replicon particle vaccine 
(RP) administered to swine was able to induce high antibody HI titers against a human 
influenza strain. A subsequent study using an RP vaccine expressing the HA protein of a 
clade IV H3N2 SIV isolate confirmed that influenza HA RP vaccines given to swine are 
not only able to induce an antibody response, but also provide significant protection 
against a homologous viral challenge.  In contrast to these earlier studies, this study used 
an alphavirus replicon expression system to produce recombinant HA protein in vitro; 
however, similar antibody responses and protection from viral challenge was 
demonstrated.  
The results demonstrate that influenza infection of swine with 
A/California/04/2009 influenza virus is able to induce clinical symptoms and gross 
lesions comparable to other strains of SIV.
18-20
  In contrast with a previous study, several 
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pigs (primarily in the non-vaccinated group) in this study exhibited clinical signs, mainly 
coughing and sneezing.  This discrepancy may be due to the miniature pig model used in 
that study.
8
  In this study, vaccine administration induced specific antibody titers, reduced 
macroscopic and histopathologic lung lesions, and reduced viral load in both the nose and 
lung.  Recombinant HA vaccinated pigs also demonstrated a higher average daily gain 
than placebo vaccinated pigs. These results demonstrate that this recombinant pandemic 
HA protein is efficacious when used as a vaccine against pH1N1 swine influenza. 
Several recent studies have already reported the successful transmission of 
pandemic H1N1 virus from infected to naïve contact pigs.
2,10
  The successful 
transmission of this virus among pigs and recent confirmation of its presence in the 
United States demonstrates the need for an efficacious pandemic H1N1 vaccine.  This 
paper shows that vaccination of pigs against pandemic H1N1 can reduce both clinical 
symptoms and virus shedding in pigs, which may lead to decreased transmission. 
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Figure 1. Western blot confirming recombinant HA protein expression.  
Lane 1, Ladder; Lane 2, Vero lysate (negative control);  
Lane 3, recombinant HA (28.5µg/ml); Lane 4, recombinant HA (0.57µg/ml); 
Lane 5, recombinant HA (0.285µg/ml); Lane 6, recombinant HA (0.19µg/ml) 
 
 
 
 
Table 1: Design of pandemic H1N1 recombinant HA vaccine study.   
Pigs received either placebo vaccine (PBS, Group 1) or varying doses  
of HA antigen (Groups 2-4).  All vaccines were given intramuscularly  
as 2ml doses on days 0 and 21. 
Group Vaccine HA concentration/dose 
1 
2 
3 
4 
Placebo 
Recombinant HA 
Recombinant HA 
Recombinant HA 
0.00µg 
1.14µg 
0.57µg 
0.38µg 
  
 
 
 
 
 
 
 
HA protein 
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Table 2.  Summary of hemagglutination inhibition (HI) titers, average macroscopic and microscopic 
 lung involvement, immunohistochemistry (IHC), and average daily gain (ADG). 
Group  HI Titersa  % Pneumoniab 
Histopathologic 
Scorec  Lung IHCd ADGe 
1  <10  15.6 ± 5.4 1.8 ± 0.1  5/5 1.76 ± 0.2 
2  121*  1.4 ± 0.9* 0.8 ± 0.2*  1/5 2.56 ± 0.68 
3  184*  0.2 ± 0.2* 0.6 ± 0.2*  0/5 2.64 ± 0.22* 
4  106*  1.8 ± 1.1* 0.8 ± 0.2*  1/5 2.45 ± 0.34* 
aGeometric mean homologous HI titers 
bGroup mean ± standard error 
c0-3, group mean ± standard error 
dNumber of positive samples per group 
eADG post-challenge in pounds, group mean ± standard error 
*Values are significantly different from placebo vaccinates (Group 1) within a column at p<0.05 
 
 
 
 
 
 Table 3. Summary of live virus isolation from nasal swabs and bronchoalveolar lavage fluid (BALF). 
 
Group 
Nasal Swabsa BALFb 
1dpcc 2dpc 3dpc 4dpc 5dpc 5dpc 
1 0 0.85 ± 0.53 2.55 ± 0.66 3.05 ± 0.18 3.05 ± 0.24 5/5 
2 0 0 0* 0* 0* 2/5 
3 0 1.05 ± 0.07 0.65 ± 0.65 0.9 ± 0.57* 1.0 ± 0.62* 0/5 
4 0 0.45 ± 0.45 0.5 ± 0.5* 0.65 ± 0.65* 0.65 ± 0.65* 1/5 
aLog10 mean virus titers ± standard error in nasal swabs post-challenge 
bNumber of positive BALF samples per group 
cDays post-challenge (dpc) 
* Values are significantly different from placebo vaccinates (Group 1) within a column at p<0.05 
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Abstract 
A single-cycle, propagation-defective replicon particle (RP) vaccine expressing a swine 
influenza virus hemagglutinin (HA) gene was constructed and evaluated in several 
different animal studies.  Studies done in both the intended host (pigs) and non-host 
(mice) species demonstrated that the RP vaccine is not shed or spread by vaccinated 
animals to comingled cohorts, nor does it revert to virulence following vaccination.  In 
addition, vaccinated pigs develop both specific humoral and IFN-γ immune responses, 
and young pigs are protected against homologous influenza virus challenge.   
Introduction 
Swine Influenza Virus (SIV) continues to be problematic in the swine industry.  Swine 
influenza virus is characterized by a sudden onset of respiratory illness, and is usually 
accompanied by anorexia, lethargy, and fever.  In addition to the clinical complications 
associated with SIV in production animals, there have been several published reports 
implicating swine in the transfer of influenza viruses to humans.
24,32,39
  Most recently, the 
2009 pandemic H1N1 influenza virus was shown to have components of swine origin.
9
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Our group has reported the rapid development of a swine vaccine against the pandemic 
H1N1 virus based on the alphavirus replicon system.
36
  In addition to the possibility of 
zoonotic transfer, swine influenza viruses within the swine population continue to evolve 
at a rapid pace.  Until 1998, swine influenza in the United States was caused almost 
exclusively by classical H1N1,
7
 originally isolated in 1930.
33
  However, in 1998 both 
double and triple reassortant H3N2 viruses emerged.
38,41,42
  Since then, there have been 
many influenza reassortment events that have led to the emergence of new subtypes and 
clusters.
5,11,12,19,30,37,40
  Commercially available SIV vaccines often do not protect against 
new and emerging virus subtypes/clusters and must be periodically updated to match 
currently circulating strains.  As such, novel swine influenza vaccines that are safe, 
effective, and can be rapidly altered to antigenically match an emerging strain should be 
considered as alternatives to traditional swine influenza vaccines.  The United States 
Department of Agriculture Center for Veterinary Biologics (USDA CVB) has guidelines 
on the design of such safety studies for modified live vaccines (Veterinary Services 
Memorandum 800.201), but to date, has no specific guidance on shed spread or reversion 
to virulence studies for recombinant replication-incompetent vaccines.  Thus, the studies 
included in this paper represent novel study designs and results that have been approved 
by the USDA CVB specifically for this replication-incompetent alphavirus-based 
replicon particle (RP) SIV vaccine. 
An alphavirus replicon vector system has been derived from the attenuated TC-83 
strain of Venezuelan equine encephalitis virus (VEEV).
14
  The ~11.4kb VEEV positive-
sense genome contains two open reading frames (ORFs). The 5’ ORF encodes four 
nonstructural proteins  (nsp1-4) and the 3’ ORF encodes the virus structural proteins 
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(capsid and glycoproteins (E3, E2, 6K and E1)).
35,27
  The nonstructural proteins are 
translated from the positive-sense genomic RNA and function to transcribe full-length 
negative-sense RNA. This negative-sense RNA is a template for both additional genomic 
RNA as well as 26S subgenomic mRNA.  The 26S promoter is located between the two 
ORFs on the negative-sense RNA and is recognized by the nonstructural proteins for 
transcription of a subgenomic mRNA, from which the structural proteins are translated.  
This 26S mRNA is produced in 10-fold molar excess when compared to genomic RNA.
35
  
Foreign genes of interest can be inserted in the place of VEEV structural genes in a 
cDNA clone generating a self-replicating RNA (replicon) capable of expressing the 
foreign gene when introduced into cells.  The self-amplifying replicon RNA directs the 
translation of large amounts of protein in transfected cells, reaching levels as high as 15-
20% of total cell protein.
26
  This replicon RNA does not contain any of the VEEV 
structural genes, so the RNA is propagation-defective.  The replicon RNA can also be 
packaged into a replicon particle (RP) by supplying the structural genes in trans in the 
form of capsid and glycoprotein helper RNAs.
18,26
  When the helper and replicon RNAs 
are combined and cotransfected into cells, the replicon RNA is efficiently packaged into 
single-cycle, propagation-defective RP. 
Early production of RP were hampered by recombination events that resulted in 
the generation of replication-competent virus (RCV)
27
; first generation helper RNAs 
encoded the capsid and glycoprotein genes on the same RNA molecule, and thus only 
required one recombination event to create RCV.
2,10,26
  The probability of this event 
occurring was greatly reduced by separating the helpers onto two separate RNAs (“split 
helper” system).  This bipartite or split conformation greatly reduced the occurrence of 
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RCV, as separation of the helper RNAs requires two independent recombination events 
to occur for generation of RCV.
26,34
  These initial versions of the helper RNAs were 
designed to contain a 26S promoter downstream of the 5’ untranslated region.  However, 
recent studies have demonstrated that the 26S promoter is not required for functional 
helper RNAs.
16
  Removal of the 26S promoter results in helper RNAs that are not 
independent transcriptional units, and further reduces the possibility of functional 
recombinations between the replicon and helper RNAs.  In addition to the removal of the 
26S promoter, a stop codon has been introduced at the 3’ end of the capsid gene in place 
of the chymotrypsin-like cleavage site.
16
  This mutation negates the cleavage activity of 
the capsid protein, adding another safeguard against functional recombination.  Thus, 
helper RNAs lacking 26S promoters and with an engineered capsid stop codon further 
reduce the probability of functional recombination than the standard split helper RNA 
system.
16
    
Alphavirus RP vaccines have been tested in multiple animal studies using 
multiple species (including humans) for more than 20 years.
3,8,15,27
  However, formal 
safety studies have not been conducted in swine previously.  We have used the alphavirus 
replicon system to produce an H3 SIV RP vaccine and we report studies performed 
evaluating the potential for this vaccine to shed, spread, and revert to virulence in both 
the intended host (pigs) and non-host (mice) species.  Immunogenicity and efficacy were 
also evaluated in pigs of different ages. 
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Material and Methods 
Replicon particle vaccine 
The HA gene was PCR amplified from a cluster 4 H3N2 SIV isolate and cloned 
into the VEEV RP vector system using previously published methods.
4
  
Pig shed spread and reversion to virulence study 
 Twenty six-week old caesarean-derived, colostrum-deprived (CDCD) pigs (12 gilts 
and 8 barrows) were obtained from Struve Labs (Manning, IA).  All pigs were confirmed 
negative for antibodies to porcine reproductive and respiratory syndrome virus (PRRSV), 
SIV H1N1 and SIV H3N2 using commercial ELISA assays (IDEXX).  The pigs were 
randomly assigned to HA RP vaccinated or placebo groups.  Upon arrival at the study 
facility, pigs were separated into five different pens located within the same room.  Each 
pen contained two H3 RP vaccinated pigs and two placebo pigs.  These two groups were 
comingled for the duration of the study, except for the 24 hours immediately following 
vaccination to prevent physical transmission of the H3 RP vaccine to placebo pigs.  The 
H3 RP vaccine was administered both intravenously (IV) in the right jugular vein and 
intramuscularly (IM) on the right side of the neck, both in 3 ml doses containing 1x10
10
 
H3 RP, for a total of 2x10
10
 H3 RP.  The placebo vaccine containing only the vaccine 
diluent was administered in identical dose volumes and injection sites.  Both vaccines 
were administered by personnel blinded to vaccine composition to avoid potential bias 
regarding vaccine reactions.  Pigs were observed daily for 14 days post-vaccination for 
any vaccine-related adverse effects.  Serum, nasal swabs and rectal swabs were collected 
on study days -1, 0, 3, 7, 10, and 14.  Nasal and rectal swabs were placed into 15 ml 
conical tubes containing 1ml minimum essential media (MEM) (Invitrogen Life 
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Technologies) + 1% antibiotic/antimycotic (Invitrogen Life Technologies).  Samples 
were held at -80°C until removal for further processing.  Tissues collected at necropsy 
included injection site (right neck musculature), tonsil, spleen, heart, lung, right 
retropharyngeal lymph node, liver, intestine, brain, and kidney.  Tissues were placed in 
whirl-pak bags at necropsy and held at -80°C until removal for further processing.  
Samples collected throughout the study were assayed by the RT-PCR and CPE assays.  
All pigs were housed and treated in accordance with IACUC approved guidelines.  
Mouse shed spread and reversion to virulence study 
Twenty six-week old BALB/c female mice were obtained from Charles River 
Laboratories (Portage, MI).  The twenty mice were divided equally among five cages, 
with each cage containing two mice injected with H3RP vaccine and two mice injected 
with placebo vaccine.  Mice were identified within a cage by unique individual ear 
notches.  The two groups were comingled for the duration of the study, except for the 24 
hours immediately following vaccination on study days 0 and 14 to prevent physical 
transmission of the H3 RP vaccine to the placebo mice.  The H3 RP vaccine was 
delivered intraperitoneally in 200µl doses containing 3x10
7
 SIV RP.  The placebo 
vaccine was administered in identical dose volumes and injection sites.  Both vaccines 
were administered by personnel blinded to vaccine composition to avoid potential bias 
regarding vaccine reactions.  Fecal pellets were collected from each cage at multiple time 
points throughout the study.  Blood was collected post-euthanasia via cardiac puncture.  
Tissues collected at necropsy included brain, liver, heart, kidney, spleen, lungs, and 
intestine.  A portion of each tissue was placed into individual microcentrifuge tubes, and 
a portion of the tissue samples were also fixed in 10% buffered formalin for 
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histopathological analysis.  All samples collected throughout the study and at necropsy 
were held at -80°C freezer until removal for further processing.  Samples collected 
throughout the study were assayed by the RT-PCR and CPE assays.  All mice were 
housed and treated in accordance with IACUC approved guidelines. 
H3 RP vaccine immunogenicity study 
Eighteen first parity gilts were obtained from Wilson’s Prairie View Farm, Inc. 
(Burlington, WI).  All gilts were confirmed negative for antibodies to PRRSV and SIV.  
Gilts were randomized equally into three treatment groups.  Group 1 received H3 RP, 
group 2 received PRRSV RP, and group 3 received no treatment.  Groups 1 and 2 
received respective RP vaccines at a dose of 2x10
9 
IM on study days 0 and 21.  Serum 
and peripheral blood mononuclear cells (PBMC) were collected at 15 days post-booster 
vaccination for homologous HI testing and IFN-γ ELISPOT, respectively.   
H3 RP vaccine efficacy study 
Fifty three-week old pigs (27 gilts and 23 barrows) were obtained from Wilson’s 
Prairie View Farm, Inc. (Burlington, WI).  All pigs were confirmed negative for 
antibodies to PRRSV and influenza nucleoprotein (ELISA), and SIV H1N1 and SIV 
H3N2 (HI).  In addition, all pigs were negative for antibodies against the homologous 
cluster 4 H3N2 SIV strain used in the study as determined by HI assay.  Pigs were 
randomized by litter to treatment groups and housing units.  Treatment groups consisted 
of 20 H3 RP vaccinates, 20 placebo vaccinates, and 10 strict negative controls.  All the 
pigs were housed in the same room in 2 separate pens, each pen containing 10 H3 RP 
vaccinates, 10 placebo vaccinates, and 5 strict controls.  H3 RP vaccinated pigs received 
a 2ml dose containing 1x10
8
 RP administered IM on study days 0 and 21.  The placebo 
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vaccine containing only the vaccine diluent was administered in identical dose volumes 
and injection sites.  The strict controls were not vaccinated at any time throughout the 
study.  Both vaccines were administered by personnel blinded to vaccine composition to 
avoid potential bias regarding vaccine reactions and clinical observations.  Pigs were 
observed daily throughout the study for vaccine-related adverse effects.  On study day 56 
(35 days post-booster vaccination) the H3 RP and placebo vaccinated pigs were 
challenged intratracheally with the homologous (to the H3 RP vaccine) cluster 4 H3N2 
SIV strain at a dose of 1x10
7
 TCID50 in a 10ml volume.  The strict controls were not 
challenged and were moved to a separate room prior to challenge.  Body temperatures 
were collected from each pig pre- and post-challenge using injectable RFID chips and a 
hand-held scanner (Destron Fearing).  Nasal swabs were collected daily beginning on the 
day of challenge until necropsy for live virus titration.  Pigs were euthanized and 
necropsied 4 days post-challenge.  At necropsy, each lung lobe affected by pneumonia 
was visually estimated by a blinded board-certified veterinary pathologist, and a total 
percentage for the entire lung was calculated based on weighted proportions of each lobe 
to the total lung volume.
13
  A portion of each lung lobe was collected in 10% buffered 
formalin for histopathological analysis and scored as described previously.
30
  
Bronchoalveolar lavage fluid (BALF) samples were collected from each pig at necropsy 
for live virus titration.  
RNA extraction and RT-PCR 
RNA was extracted from serum samples using the Qiagen QIAamp Viral RNA 
Mini Kit according to the manufacturer’s instructions.  RNA was extracted from feces 
and all tissues using the Qiagen QIAshredder and the Qiagen RNeasy Mini Kit according 
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to the manufacturer’s instructions.  Briefly, feces and tissue samples were mixed with an 
appropriate amount of Buffer RLT and homogenized using ground glass tissue grinders.  
Homogenates were run through individual QIAshredder columns, and RNA was 
extracted as per the RNeasy Mini Kit protocol.  RT-PCR was performed using the Qiagen 
OneStep RT-PCR Kit with 5 µl of RNA template.  Primers were designed to amplify a 
300 base pair segment of the SIV H3 gene contained in the SIV H3 RP vaccine.  Primer 
sequences were SIV H3-RP-For (5’GCATATTCGGCGCAATAGCAGGTT-3’) and SIV 
H3-RP-Rev (5’-GCAACAAGAAGCTCCGCGTTGTAA-3’).  Swine influenza virus 
H3N2 HA RNA and nuclease-free water were included in each PCR run as positive and 
negative controls, respectively.  Cycle conditions were 58°C for 30 minutes, 95°C for 15 
minutes, 30 cycles of 95°C for 30 seconds, 58°C for 30 seconds, and 72°C for 1 minute, 
and a final hold at 4°C.  PCR products were then separated by electrophoresis on a 2% 
agarose gel, visualized and photographed using ultraviolet light on a BioRad GelDoc.  
The limit of detection for this assay was determined by calculating the number of PCR 
copies visually detected by UV illumination of serially diluted in vitro transcripts of the 
H3 replicon.  
Cytopathic effect (CPE) assay 
Samples (including serum, swabs, and tissues) obtained throughout the studies 
were evaluated for the presence of RCV by the CPE assay.  Tissue samples were 
prepared by adding 2 parts MEM + 1% antibiotic/antimycotic to 1 part (v/w) of 
respective tissue and homogenizing with a ground glass tissue grinder.  The homogenate 
was centrifuged, and the resulting supernatant was used for the CPE assay.  No further 
processing was done on serum before the CPE assay.  The following CPE assay is 
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adapted from the published CPE assay method.
17
  Each serum and tissue sample collected 
throughout the study was used to inoculate one well of a 48 well plate containing a 
monolayer of Vero cells.  After 1 hour incubation at 37°C/5% CO2, samples were 
decanted, all wells were washed three times with PBS, and fresh MEM placed on the 
cells.  After 24 hours incubation, media supernatants were transferred to a fresh Vero cell 
48 well plate and incubated for 1 hour.  After incubation, media was decanted, cells 
washed three times with PBS, and fresh MEM added to cells.  After an additional 72 
hours of incubation, the cells were examined microscopically for CPE.  Cells were then 
fixed and stained using a 10% formalin solution with 0.25% crystal violet.  This method 
also allowed for macroscopic evaluation of the cells for CPE.  MEM was used as a 
negative control and green fluorescent protein (GFP) RP was used as a positive control to 
ensure RP infection of Vero cells.  The CPE assay has a limit of detection of 1 PFU of 
replication-competent TC-83 VEE virus in the presence of 1x10
10
 replicon particles 
(Kamrud unpublished results). 
IFN-γ ELISPOT 
The IFN-γ ELISPOT was performed using a modification of previously described 
methods.
43
  Briefly, Millipore Multi-Screen filter 96 well plates were pre-wet with 70% 
ethanol, washed with PBS, coated with purified mouse anti-swine IFN-γ (BD 
Biosciences), and incubated overnight at 4°C. Following incubation, plates were washed 
with RPMI media (Sigma-Aldrich) and blocked for 1 hour at room temperature with 
RPMI containing fetal bovine serum and antibiotics (complete RPMI).  After blocking, 
the media was decanted and each PBMC sample was plated in replicates at a 
concentration of 2e5 PBMC/well.  PBMC plus complete RPMI was used as the 
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unstimulated negative control and PBMC plus PHA-P at 10μg/ml was used as the 
positive control.  PBMC were plated in duplicates and then stimulated with whole virus 
H3N2 influenza virus supernatant at a titer of 1x10
6
 TCID50.  The plates were incubated 
with the stimulating antigens for 18-22 hours at 37°C.  After incubation, the plates were 
washed with 1x KPL wash solution. Bioatinylated mouse anti-swine IFN-γ (BD 
Biosciences) was added to each well and incubated for 1 hour at 37°C.  After washing, 
alkaline phosphate labeled streptavidin (Bio-Rad) was plated and incubated for 1 hour at 
37°C.  Plates were developed for 3 to 10 minutes using an alkaline phosphatase substrate 
kit (Bio-Rad).  Positive spots were enumerated using a Zeiss ELISPOT reader system 
(Zellnet Consulting Inc.)  The number of IFN-γ producing PBMC was determined by 
subtracting the number of spots from the wells stimulated with antigen from the wells 
with no stimulation. This number was then normalized to spot forming cells/1x10
6
 
PBMC. 
Live virus titration 
Nasal swab and BALF samples were subsequently thawed and vortexed.  The 
swabs were removed and tubes were centrifuged to pellet cell debris.  One milliliter of 
media was removed without disturbing the pellet and transferred to a sterile 
microcentrifuge tube for live virus titration.  Serial 10-fold dilutions of the sample were 
performed in MEM supplemented with TPCK-Trypsin (Thermo Scientific) and 
antibiotic/antimycotic. 100μl of each dilution was transferred to confluent MDCK cells in 
96 well plates and incubated for 3 days at 37°C/5% CO2.  Following incubation, cells 
were fixed with a 70%/30% acetone/methanol solution and washed with PBST.  Infected 
cells were visualized by IFA using a mouse monoclonal antibody specific for the 
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Influenza A nucleoprotein with high specificity for N2/N3 type Flu A (Millipore) and 
Alexa Fluor 488 donkey anti-mouse IgG (H+L) (Invitrogen Life Technologies).  Plates 
were observed using an inverted fluorescent microscope to count infected cells.  Titers 
were determined using the Reed-Muench equation.
29
 
Statistical analysis 
Analysis of variance (ANOVA) was used to analyse inverse homologous HI 
titers, ELISPOT counts, and log10 transformed live virus titrations.  The non-parametric 
Wilcoxin rank sum test was used for gross and histopathological lung score analysis.  
Analyses were performed using the JMP software (SAS, Cary, NC). Statistical 
significance was set at p<0.05. 
Results 
Shed spread/reversion to virulence studies 
All of the samples collected in both the pig and mice shed spread studies, including 
tissues, serum, nasal and rectal swabs, and fecal pellets, were tested by an H3-specific 
RT-PCR assay to determine if the H3 RP vaccine demonstrated any capacity for shed or 
spread.  No H3-specific RNA was detected in any of the samples taken from H3 RP or 
placebo vaccinated animals.  The limit of detection for the RT-PCR assay was 
determined to be 1.5x10
3
 copies per reaction.   Homologous HI tests were conducted on 
pig serum collected at necropsy (14 days post-vaccination) to demonstrate that the RP 
vaccine was indeed functional.  All of the pigs receiving the H3 RP vaccine developed 
positive HI titers ranging from 20-80 (GMT = 57, data not shown), while all of the pigs 
receiving placebo vaccine were negative at the conclusion of the study.  
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Histopathological analysis demonstrated that there were no significant lesions identified 
in either H3 RP or placebo vaccinated mice, and none of the non-specific lesions were 
consistent with either VEEV or SIV infection.  Samples collected in both the pig and 
mice shed spread studies were negative for any RCV following two blind passages on 
Vero cells by both microscopic and macroscopic evaluation.   
Immunogenicity study 
When the homologous H3N2 virus was used as the stimulating antigen in the 
ELISPOT assay, there was a specific IFN-γ response in gilts that received the H3 RP 
vaccine (Table 1).  In addition, all gilts receiving the H3 RP vaccine demonstrated high 
homologous HI titers at 15 days post-boost (Table 1).  
Efficacy study  
The homologous H3N2 HI serum antibody titers are shown in Table 2.  At three 
weeks post-prime vaccination and prior to receiving a booster injection, 19 of the 20 H3 
RP vaccinated pigs had already developed positive HI titers ranging from 20 to 160 (data 
not shown).  A significant increase following booster vaccination was observed which 
was maintained until the day of challenge at 5 weeks post-boost.  Sera from placebo 
vaccinated pigs and the strict controls were negative for HI antibody throughout the 
study.  
 Body temperatures of pigs collected post-challenge are summarized in Table 3.  
At 1 day post-challenge, the H3 RP vaccinated pigs had significantly lower body 
temperatures than placebo vaccinated pigs.  The febrile response peaked at an average of 
40°C at 1 day post-challenge in the placebo vaccinated group after which all body 
temperatures began to decline to baseline levels. At day 1 post-challenge, 50% of the 
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placebo vaccinated pigs developed fevers (≥40°C) while only 20% of H3 RP vaccinated 
pigs developed fevers.   
Nasal shedding and lung viral titers are shown in Table 2.  The H3 RP vaccine 
prevented detectable nasal shedding at all days post-challenge, while viral shedding was 
detected in 18 of 20 placebo vaccinated pigs by day 4 post-challenge.  In addition, no live 
virus was detected in the BALF samples from the H3 RP vaccinated pigs, while all pigs 
receiving placebo vaccine had detectable virus recovered from the BALF samples. 
Macroscopic evaluation of individual lungs at necropsy exhibited pneumonic 
lesions typical of SIV with purplish-red areas of consolidation.  H3 RP vaccinated pigs 
exhibited statistically significant lower lung lesion scores than the placebo vaccinated 
animals (Table 3).  The macroscopic lung scores were similar in both non-challenged 
controls and the H3 RP vaccinated pigs. Histopathological analysis of lungs correlated 
with the macroscopic results.  Ninety percent of placebo vaccinated pigs exhibited 
epithelial disruption with interstitial pneumonia in at least 30% of the upper airways 
(score ≥ 2).  In contrast, only 20% of the H3 RP vaccinated pigs exhibited a few 
disrupted airways (score ≤ 1).   
Discussion 
The capacity for shed, spread and reversion to virulence of an SIV H3 RP vaccine 
was evaluated in both the intended host (pigs) and non-host (mice) species in a study 
design that was approved by USDA CVB.  The rational for using a 200-fold higher dose 
in the safety studies compared to the efficacy study was to conclusively demonstrate the 
safety of the vaccine even when administered at a dose orders of magnitude higher than 
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the intended dose.  An H3-specific RT-PCR assay was utilized to detect shedding of the 
RP vaccine.  If recombination event(s) were to occur resulting in replication-competent 
virus (RCV), the H3 gene would likely be partially or completely replaced by the 
structural capsid and glycoprotein genes.  However, the purpose of the RT-PCR was not 
to necessarily detect RCV, but instead to monitor various tissue and secretory samples for 
shedding of the vaccine RNA.  Even at this high dosage level, no replicon-specific RNA 
was detected in nasal and rectal swabs, serum, or tissues at any time point of sample 
collection.  These results demonstrate that the H3 RP vaccine is not shed from vaccinated 
animals nor spread to non-vaccinated cohorts or into the environment.  The assay used to 
demonstrate the absence of RCV has been shown to be very sensitive (detection of 1 PFU 
in 1x10
10
 RP, data not shown). All of the samples tested were negative for RCV 
following two blind passages in cell culture, indicating a lack of reversion to virulence to 
the parental VEEV strain.  In addition, all of the H3 RP vaccinated animals were HI 
positive by 14 days post-vaccination while none of the placebo vaccinated pigs had 
positive serum HI titers.  These results indicate that the vaccine was functional and 
further demonstrate the lack of shed and spread of the H3 RP vaccine.  We believe that 
these results support the inherent safety of the replicon system.   
This is the first report evaluating the safety profile of RP vaccines in swine.  
However, extensive safety and biodistribution studies have been completed in non-swine 
models.  Several VEEV RP toxicology studies performed in rabbits indicate no adverse 
reactions following IM and SC injections.
15,28
  Kowalski et al demonstrated that 
intracranial (IC) injection of VEEV RP resulted in only transient pathology (1-2 days) 
and weight loss (1 day) with a rapid return to pre-injection status.
20
  Vaccine RNA was 
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detectable in brain tissue for only 5-8 days following IC injection, but no RNA was 
detected when the RP was administered IV or IM, suggesting that it does not cross the 
blood-brain barrier after systemic administration.  The neurovirulence of both Sindbis 
and Semliki Forest virus (SFV) RP expressing LacZ have been evaluated following IC 
inoculation.  Βeta-galactosidase activity was detectable in brains for 14-28 days, but no 
morbidity, neuropathology, or loss of motor skills was observed in either study, 
indicating a lack of reversion to the parental virus strains.
1,21
  A biodistribution study 
done with the same SFV RP system demonstrated that following IC injection there was 
no evidence of RP RNA colocalization to either the liver or the brain after 15 days, and 
no abnormalities were observed during histopathological examination.
22
  The results from 
these non-swine studies correlate with the host (pig) and non-host (mice) species results 
presented here, specifically that no reversion to virulence was noted in vivo.   
As demonstrated by the results presented here, the current features of the VEEV 
RP system result in a safe vaccine that is not shed or spread nor does it revert to 
virulence.  However, if in such a rare circumstance the perfect pair of recombinations did 
occur in the exact order and positions needed,
16
 the resulting RCV would theoretically be 
no more virulent than the parent VEEV strain TC-83.  TC-83 has been used extensively 
to vaccinate military personnel and lab workers against VEEV infection.  A retrospective 
study of hundreds of humans who received the vaccine from 1976 to 1990 indicated that 
TC-83 vaccine caused some transient reactions, but no serious sequelae were reported.
25
  
This strongly suggests that if multiple improbable functional recombination events were 
to occur, the outcome would not have serious public health consequences. 
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The current studies also demonstrate that the VEEV RP system is an 
immunogenic and efficacious vector for swine vaccines.  Other studies have previously 
demonstrated immunogenicity and efficacy of RP expressing HA antigens.
4,8,15,26,31
  
However, the studies presented here are the first to report a specific CMI response in pigs 
and to demonstrate formal efficacy in a large controlled study.  Following H3 RP 
vaccination, both a humoral and specific IFN-γ response was observed in pregnant gilts.  
In the young pig efficacy study, IFN-γ levels were not examined, but robust HI titers 
were demonstrated out to 5 weeks post-booster vaccination.  Efficacy was demonstrated 
by preventing or reducing nasal shedding, viral replication in the lungs, body 
temperature, and lungs lesions when compared to placebo vaccinated animals.  In 
addition, only H3 RP vaccinated pigs in the efficacy study developed positive HI titers, 
while all of the controls and placebo pigs remained seronegative, further demonstrating a 
lack of shed and spread of the vaccine. Thus, the H3 RP vaccine has been shown to be a 
safe and effective alternative to traditional vaccines used to control SIV. 
Swine vaccines based on the alphavirus RP system offer many advantages over 
other traditional commercial vaccines.  First, the RP is propagation-defective.  This 
feature alleviates concerns regarding reversion to virulence in vaccinated animals.  The 
molecular safety features of the current RP vector system ensure that the risk of reversion 
to virulence is negligible, and the present studies confirm that safety in both the intended 
host (pigs) and non-host (mice) species.  Second, the H3 RP vaccine is able to 
differentiate infected from vaccinated animals (DIVA).  Current killed vaccines contain 
inactivated whole viruses, and as such induce immune responses to multiple flu antigens 
not necessarily related to a protective response.  The H3 RP vaccine contains only the HA 
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gene so it can be used in conjunction with the current diagnostic NP-specific influenza 
detection test
6
 to easily determine the infection status of an animal or herd.  Third, 
because it has been shown that vaccination in the presence of pre-existing immunity to 
RP has no or only minimal effect on inducing robust host immune response, the same RP 
vector can be used for multiple vaccinations of the same animal with no decrease 
observed in vaccine efficacy.
23,26
  This feature also allows for the same RP vector to be 
used as vaccines against different diseases.  Finally, the RP vector system can be utilized 
to include protective genes from most any pathogen.  The requirement for high-
containment laboratories to carry out research or vaccine production is not an issue with 
the RP system because genes of interest can be de novo synthesized and engineered 
directly into a replicon vector without the need for growth of the actual pathogen.  
Furthermore, because the vector is easily manipulated at a molecular level, vaccines can 
be produced quickly in response to emerging infectious diseases.
36 
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Table 1. IFN-γ ELISPOT and homologous hemagglutination inhibition  
(HI) results at 15 days post-boost vaccination.   
Group IFN-γ ELISPOTa HI Titersb 
H3 RP 203.3 ± 89.4 403.2 ± 86.8 
PRRSV RP 10.8 ± 7.1 0.0 ± 0.0 
Control 10.4 ± 8.2 0.0 ± 0.0 
aNumber of IFN-γ secreting-cells/1x106 PBMC, group mean ± SEM 
bInverse geometric mean titer (GMT), group mean ± SEM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 2. Serum homologous hemagglutination inhibition (HI) antibody titers and influenza virus titers in nasal swabs and lungs of  
vaccinated and control pigs in efficacy study. 
Group 
Homologous HI Titersa Log10 Virus Titers
b 
Pre-Vac 0dpb 7dpb 35dpb NS 3dpc NS 4dpc BALF 
Placebo/Ch 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.0 ± 0.3 2.8 ± 0.3 4.2 ± 0.2 
H3 RP/Ch 0.0 ± 0.0 33.3 ± 8.2 ≥320.0 ± 40.0 ≥234.3 ± 48.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Control/NoCh 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Ch: Challenged; NoCh: Not Challenged; dpb: days post-booster vaccination; NS: nasal swabs; dpc: days post-challenge 
aInverse geometric mean titer (GMT), group mean ± SEM 
bSIV TCID50/ml log10 titers. No live virus detected at 0, 1, and 2 days post-challenge in any group.  Group mean ± SEM 
 
 
 
 
Table 3. Body temperature, gross and microscopic lung lesions of vaccinated and control pigs in efficacy study. 
Group 
Body Temperature (°C)1 
Gross Lung 
Scores2 
Histopathological 
Lung Scores3 1dpc 2dpc 3dpc 4dpc 
Placebo/Ch 40.0 ± 0.1a 38.4 ± 0.1a 38.4 ± 0.1a 38.8 ± 0.1a 18.7 ± 1.8a 2.3 ± 0.1a 
H3 RP/Ch 39.1 ± 0.2b 38.1 ± 0.1a 38.3 ± 0.2a 38.3 ± 0.2b 2.6 ± 1.3b 0.2 ± 0.1b 
Control/NoCh 38.4 ± 0.2c 38.3 ± 0.2a 38.6 ± 0.2a 38.6 ± 0.2ab 1.1 ± 0.5b 0.0 ± 0.0b 
Ch: Challenged; NoCh: Not Challenged; dpc: days post-challenge 
1Group mean ± SEM 
2Total percentage (%) of lung affected by macroscopic pneumonic lesions [31], group mean ± SEM 
3Scores are based on a 0-3 scale [13], group mean ± SEM 
a,b,cGroups with different letter superscripts are significantly different at p≤0.05
8
1
 
82 
 
CHAPTER 5. VARYING LEVELS OF PROTECTION AGAINST PANDEMIC 
H1N1 IN PIGS FOLLOWING HEMAGGLUTININ AND NUCLEOPROTEIN 
REPLICON PARTICLE VACCINATION 
A manuscript submitted to Veterinary Microbiology 
 
Ryan L. Vander Veen, Mark A. Mogler, Brandon J. Russell, Alan T. Loynachan,  
D.L. Hank Harris, Kurt I. Kamrud
 
Abstract 
The emergence of the pandemic H1N1 (pH1N1) influenza virus in 2009 
highlights the zoonotic potential of influenza viruses and also the need for vaccines 
capable of eliciting heterosubtypic protection.  In these studies single-cycle, propagation-
defective replicon particle (RP) vaccines expressing influenza hemagglutinin (HA) and 
nucleoprotein (NP) genes were constructed and efficacy was evaluated in homologous 
and heterologous animal challenge studies with the pH1N1 influenza virus.  Homologous 
HA RP vaccination protected pigs against pH1N1 challenge. An RP vaccine expressing 
an H3N2-derived NP gene was able to decrease nasal shedding and viral load following 
heterosubtypic pH1N1 challenge in pigs.  These studies indicate that although 
homologous vaccination remains the most effective means of preventing pH1N1 
influenza infection, other vaccine alternatives do offer a level of heterosubtypic 
protection and should continue to be evaluated for their ability to provide broader 
protection. 
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Introduction 
The recent emergence of the pandemic H1N1 (pH1N1) influenza strain in the 
global human and animal populations highlights the zoonotic potential of influenza 
viruses.  This 2009 pH1N1 influenza virus has been shown to contain genes that are of 
swine origin.
8
  In addition to the pandemic strain, there have been several published 
reports of zoonotic transfer of influenza viruses from pigs to humans.
16,22,29
  In addition, 
many subtypes and clusters of swine influenza virus (SIV) currently co-circulate among 
the United States swine population.
4,11,20,28,33
  Thus, vaccination against SIV represents 
the best option for decreasing clinical complications in swine as well as decreasing 
opportunities for zoonotic spread from swine to humans.   
Studies have shown that homologous vaccination against the pH1N1 virus 
represents the most efficacious vaccine option, although there appears to be some cross-
protection from non-homologous vaccines that contain influenza strains from the same 
phylogenetic cluster.
30,31
  Recently, our group reported the rapid development of a 
recombinant hemagglutinin (HA) protein vaccine for swine against pH1N1 using the 
alphavirus replicon system.
26
  Because only the HA gene sequence is required to begin 
vaccine production using the alphavirus replicon platform system and not the actual virus 
isolate, replicon-based vaccines can be produced more rapidly than traditional inactivated 
vaccines in response to emerging viruses. The replicon system has been used to express 
genes from numerous pathogens in addition to influenza virus, including simian 
immunodeficiency virus, Norwalk virus, Ebola virus, Lassa virus, and equine arteritis 
virus.
18
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The alphavirus replicon system has been used to produce influenza HA vaccines 
for evaluation in several different species, including poultry, humans, and swine.
2,7,14,21
  
However, the recent pH1N1 outbreak has increased interest in producing universal 
influenza vaccines that offer heterosubtypic protection.  The main area of research in 
developing universal influenza vaccines has focused on the use of conserved antigens, 
such as nucleoprotein (NP) or M2 protein, to elicit broadly reactive immune responses.  
The NP is very highly conserved, with ~89% homology among 955 sequences from wild 
and domestic birds, humans, swine and equine.
37
  Traditionally, it was thought that the 
immune response to NP was dictated mainly by cytotoxic CD8
+
 T cells
36
 and cytokine-
secreting CD4
+ 
T cells.
25
  However, there is evidence that both NP-specific antibodies 
and cell-mediated immunity (CMI) play important roles in protection from influenza 
challenge.
3,5,17
  Thus, a vaccine that is capable of inducing both an anti-NP antibody and 
a cell-mediated immune response is needed to provide sufficient heterosubtypic 
immunity.  Replicon particle (RP) vaccines have been shown to induce robust antibody 
responses in swine,
2,7
 and to increase interferon-gamma (IFN-γ) producing cells14 and 
CD8
+
 T cells.
27
 
In the present studies we utilize the alphavirus replicon system to produce RP 
vaccines expressing influenza HA and NP genes.  These vaccines were evaluated in pigs 
and tested for efficacy following virulent A/California/04/2009 pH1N1 challenge.   
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Materials and Methods 
Replicon particle vaccine production  
The pandemic H1N1 (pH1N1) A/California/04/2009 influenza virus 
hemagglutinin (HA) nucleotide sequence was retrieved from the Global Initiative on 
Sharing Avian Influenza Data (GISAID) database.  The nucleoprotein (NP) nucleotide 
sequence was determined from a cluster 4 H3N2 SIV field isolate.  These sequences were 
optimized for expression and de novo synthesized (DNA2.0).   The genes were 
synthesized with unique 5’ and 3’ restriction sites which allowed insertion into the 
alphavirus replicon platform and an optimized construct was selected as previously 
described.
15
  RNA transcripts were produced in vitro and, along with TC-83 structural 
genes, mixed with Vero cells in electroporation cuvettes, pulsed, and incubated overnight 
prior to harvest as previously described.
15
  The resulting RP titers were determined using 
replicon-specific immunofluorescence assays.   
Study 1: Homologous pH1N1 HA RP efficacy study 
Ten three-week old pigs were obtained from Wilson’s prairie View Farms 
(Burlington, WI).  All pigs were confirmed negative for antibodies to porcine 
reproductive and respiratory syndrome virus (PRRSV) and SIV by commercial ELISAs 
(IDEXX). In addition, all pigs were confirmed to be negative for pH1N1 antibodies by 
the hemagglutination inhibition (HI) assay.  The pigs were randomly and equally 
assigned to one of two treatment groups: HA RP vaccine or placebo vaccine (vaccine 
diluent only).  The HA RP was administered intramuscularly at a 1x10
8
 RP/2ml dose.  
The first dose of vaccine was administered to pigs on study day 0 and booster vaccination 
given on study day 21.  Sera samples were collected throughout the study to evaluate 
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serum antibody HI titers.  On study day 47 all pigs were challenged intratracheally with 
virulent A/California/04/2009 pH1N1 influenza virus at a dose of 2x10
5
 TCID50.  Nasal 
swabs were collected daily following challenge by swabbing each naris with a polyester 
tipped swab and placing in a 15ml conical tube containing Minimum Essential Media 
(MEM) plus antibiotics/antimycotic (Invitrogen Life Technologies).  All pigs were 
euthanized and necropsied 5 days post-challenge.  Each lung lobe was grossly examined 
by a board-certified veterinary pathologist blinded to the experimental groups, and a total 
percentage of each lung affected by pneumonia was calculated based on weighted 
proportions for each lobe to the total lung volume.
12
  A portion of each lung lobe was 
collected in 10% buffered formalin for histopathological analysis and scored as described 
previously.
20
  Each lung lobe was also evaluated for the presence of SIV antigen by SIV-
specific immunohistochemistry (IHC) staining.  Bronchoalveolar lavage fluid (BALF) 
samples were collected from each pig at necropsy by pipetting MEM plus 
antibiotics/antimycotic into the trachea followed by gentle massaging of the lobes and 
subsequent recovery of the media. Nasal swabs and BALF samples were frozen at -80°C 
until use in the live virus titration assay. All pigs were weighed immediately prior to 
challenge and again post-mortem at necropsy for determination of average daily gain 
(ADG).  All animal studies were performed using protocols approved by the Iowa State 
University Institutional Animal Care and Use Committee. 
Study 2: NP RP efficacy study 
Twenty three-week old pigs were obtained from Wilson’s Prairie View Farms 
(Burlington, WI).  All pigs were confirmed negative for antibodies to PRRSV and SIV as 
described above.  The pigs were randomly and equally assigned to one of two treatment 
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groups: NP RP vaccine or placebo vaccine (RP expressing an irrelevant gene of interest, 
PRRSV Membrane protein).   Both RP vaccines were administered intramuscularly at a 
dose of 1.2x10
9
 RP/2ml.  The first dose of vaccine was administered on study day 0 and 
booster vaccination given on study day 21. Sera samples were collected throughout the 
study to evaluate NP ELISA antibody titers.  On the day of boost and day of challenge 
whole blood samples were collected for the isolation of peripheral blood mononuclear 
cells (PBMC) for subsequent use in the IFN-γ assay.  On study day 42 all 20 pigs were 
challenged transtracheally with virulent A/California/04/2009 pH1N1 influenza virus at a 
dose of 2x10
5
 TCID50.  All pigs were euthanized and necropsied 5 days post-challenge.  
Post-challenge samples were collected as described for Study 1.   
Live virus titration 
Nasal swab and BALF samples were subsequently thawed and vortexed.  The 
swabs were removed and tubes were centrifuged to pellet cell debris.  One milliliter of 
media was transferred to a sterile microcentrifuge tube for use in the live virus titration 
assay.  Serial 10-fold dilutions of the samples were performed in MEM supplemented 
with TPCK-Trypsin (Thermo Scientific) and antibiotics/antimycotic. Each dilution was 
transferred to confluent MDCK cells in 96 well plates and incubated for 3 days at 
37°C/5% CO2.  Following incubation, cells were fixed with a 70%/30% 
acetone/methanol solution and washed with PBS.  Infected cells were visualized by IFA 
using a mouse monoclonal antibody specific for the Influenza A nucleoprotein with high 
specificity for N1 type Flu A (Millipore) and Alexa Fluor 488 donkey anti-mouse IgG 
(H+L) (Invitrogen Life Technologies).  Plates were observed using an inverted 
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fluorescent microscope to determine infected cells.  Titers were determined using the 
Reed-Muench equation.
19
 
IFN-γ ELISPOT 
The IFN-γ ELISPOT was performed using a modification of previously described 
methods.
39
  Briefly, Millipore Multi-Screen filter 96 well plates were pre-wet with 70% 
ethanol, washed with PBS, coated with purified mouse anti-swine IFN-γ (BD 
Biosciences), and incubated overnight at 4°C. Following incubation, plates were washed 
with RPMI media (Sigma-Aldrich) and blocked for 1 hour at room temperature with 
RPMI containing Fetal Bovine Serum and antibiotics (complete RPMI).  After blocking, 
the media was decanted and each PBMC sample was plated in replicates at a 
concentration of 2x10
5
 PBMC/well.  PBMC plus complete RPMI was used as the 
unstimulated negative control and PBMC plus PHA-P at 10μg/ml was used as the 
positive control.  PBMC were plated in duplicates and then stimulated with whole virus 
H3N2 or pH1N1 supernatants at titers of 1x10
6 
TCID50.  PBMC collected on the day of 
challenge were also stimulated with NP RP at a titer of 1x10
6
 RP.  The plates were 
incubated with the stimulating antigens for 18-22 hours at 37°C.  After incubation, the 
plates were washed with 1x KPL wash solution. Biotinylated mouse anti-swine IFN-γ 
(BD Biosciences) was added to each well and incubated for 1 hour at 37°C.  After 
washing, alkaline phosphate labeled streptavidin (Bio-Rad) was plated and incubated for 
1 hour at 37°C.  Plates were developed for 3 to 10 minutes using an alkaline phosphatase 
substrate kit (Bio-Rad).  Positive spots were enumerated using a Zeiss ELISPOT reader 
system (Zellnet Consulting Inc.).  The number of IFN-γ producing PBMC was 
determined by subtracting the number of spots from the wells with no antigen stimulation 
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from the wells stimulated with antigen. This number was then normalized to IFN-γ 
secreting cells/1x10
6
 PBMC. 
Statistical analysis 
Analysis of variance (ANOVA) was used to analyze reciprocal HI titers, ELISA 
titers, ELISPOT counts, log10 transformed live virus titers, average daily gain, and gross 
and histopathological lung scores.  Analyses were performed using the JMP software 
(SAS).  Statistical significance was set at p<0.05.   
Results 
Homologous pH1N1 HA RP efficacy study 
All pigs in the HA RP vaccinated group developed positive HI titers by 14 days 
post-boost vaccination and maintained similar titers until challenge, while all pigs in the 
placebo group remained seronegative throughout the entire study (Table 1).  In addition 
to homologous HI titers, pandemic HA RP vaccination induced positive HI titers against 
other gamma-cluster H1N1 virus isolates (Table 1).   
No live virus was detected in nasal swabs at any day post-challenge in the HA RP 
vaccinated group.  In contrast, all five pigs in the placebo vaccinated group had 
detectable nasal swab virus titers at days 4 and 5 post-challenge (Table 2).    Live virus 
was detected from all five BALF samples from the placebo vaccinated pigs, while only 
one BALF sample contained live virus in the HA RP vaccinated group (data not shown).   
Macroscopic evaluation of lungs exhibited lesions consistent with SIV infection 
and consisted of variably sized, firm, and consolidated red foci located primarily in the 
cranioventral lung fields.  The HA RP vaccinated pigs exhibited reduced lung lesion 
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scores when compared to placebo vaccinated pigs (Table 2).  The lower macroscopic 
lung scores in the HA RP group correlated with the microscopic analysis and SIV IHC 
results.  Lung samples taken from HA RP vaccinated pigs exhibited significantly less 
microscopic pneumonia than placebo vaccinated pigs (Table 2).  All five lungs collected 
from the placebo pigs had detectable SIV antigen as demonstrated by IHC, while no SIV 
antigen was detected in any of the lungs taken from the HA RP vaccinated pigs.  In 
addition to decreased pulmonary pathology, the HA RP vaccinated pigs demonstrated 
increased average daily gain post-challenge when compared to placebo vaccinated 
animals (Table 1). 
NP RP efficacy study 
The pigs in the NP RP vaccinated group developed robust antibody titers while all 
the pigs in the placebo vaccinated group remained seronegative throughout the study 
(Table 3).  All of the pigs in the NP RP vaccinated group developed positive NP ELISA 
titers prior to booster vaccination.  The NP antibody titers increased significantly 
following boost and remained at high levels until the day of challenge (Table 3).   
Nucleoprotein RP vaccination also induced an antigen-specific CMI response as 
measured by the IFN-γ ELISPOT assay.  By 21 days post-primary vaccination and again 
on the day of challenge, the pigs receiving the NP RP vaccine demonstrated a 
significantly elevated IFN-γ response to both H3N2 and pH1N1 influenza viruses when 
compared to the placebo vaccinated pigs.  The group receiving the NP RP vaccine had a 
significantly higher number of IFN-γ secreting cells than the placebo vaccinated animals 
on the day of challenge when NP RP was used as the stimulating antigen. 
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No live virus was detected from the NP RP vaccinated pigs at 24 hours post-
challenge, while two of the placebo vaccinated pigs were shedding live virus.  By day 3 
post-challenge all pigs in the placebo vaccinated group were shedding virus, and all pigs 
in the NP RP vaccinated group were shedding virus by day 4 post-challenge.  There were 
no significant differences in the number of pigs between groups that were shedding virus 
at any day post-challenge.  However, pigs that received the NP RP vaccine shed 
significantly less virus than placebo vaccinated pigs on days 3, 4, and 5 post-challenge.  
The BALF viral titers were also significantly lower in the NP RP vaccinated pigs than 
placebo vaccinated pigs.   
The gross lesions observed at necropsy were consistent with typical SIV infection.  
These macroscopic lung scores were not significantly different between the two 
vaccination groups (data not shown). 
Discussion 
This is the first study to demonstrate the efficacy of an alphavirus RP vaccine 
against pH1N1 in pigs.  Although RP vaccines expressing the HA protein have been 
evaluated previously,
2,7,14,21
 this is the first study evaluating NP RP in pigs using a 
heterosubtypic vaccination challenge model.  Studies have shown that homologous 
vaccination against the pH1N1 virus represents the most efficacious vaccine option, 
although there appears to be some cross-protection from non-homologous vaccines that 
contain influenza strains from the same phylogenetic cluster,
30
  Those previous results 
correlate with the results reported here, and demonstrate that an HA RP vaccine is as 
effective as inactivated whole virus vaccination against pH1N1.  The homologous HA RP 
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vaccine used in this study eliminated nasal shedding in all vaccinated animals, and also 
protected against pulmonary pathology.  In addition, HA RP vaccinated animals 
demonstrated increased weight gain in the five days following virulent pH1N1 challenge, 
similar to a previous study evaluating alphavirus replicon-produced recombinant pH1N1 
HA vaccines,
26
  These results indicate that, in addition to eliminating nasal shedding and 
decreasing pulmonary pathology associated with pH1N1, HA RP vaccination can also 
increase the production performance of these economically important food animals.  
Several studies have reported enhanced pneumonia following inactivated whole 
virus vaccination and subsequent heterologous challenge.
9,32
  Although the reason for this 
phenomenon has not yet been elucidated, it is possible that the enhancement is the result 
of non-HA specific immune responses.  Heinen et al. reported enhanced disease 
following M2e/NP DNA vaccination, and implicated M2e-specific antibodies in the 
exacerbation of clinical disease.
13
 It is probable that enhancement of disease occurs to 
some extent in the field due to the widespread use of inactivated influenza vaccines in 
swine.  Swine influenza virus vaccines expressing only the HA antigen may be able to 
circumvent this enhancement, but additional research with these vaccines is required to 
further elucidate the mechanism of enhancement.   
In this study we report HI cross-reactivity to additional H1-gamma isolates 
following pH1N1 HA RP vaccination.  Although this has been previously reported,
30,31
 
these results demonstrate that pH1N1 HA RP vaccination is able to offer some level of 
protection against H1-gamma SIV strains without the requirement for both gamma and 
pH1N1 strains to both be included in a single vaccination.  In addition, there was no 
seroconversion to the vaccine antigen in any of the placebo vaccinated pigs in either 
93 
 
study, further confirming the lack of shed/spread, reversion to virulence, and overall 
safety of RP vaccines.  
Current SIV vaccines often fail to protect against emerging strains and offer only 
limited protection against heterosubtypic challenge.  This has resulted in the 
implementation of new procedures by the U.S Department of Agricultures’ Center for 
Veterinary Biologics (USDA CVB) to expedite the licensure process required for the 
addition or substitution of new SIV strains to existing vaccines (Veterinary Services 
Memorandum No. 800.111), and has led to increased evaluation of broadly-protective or 
universal vaccines that offer heterosubtypic protection.  In this study we vaccinated pigs 
with an RP vaccine expressing the NP gene derived from a cluster 4 H3N2 SIV isolate 
and challenged with the heterosubtypic pH1N1 influenza strain.  Recombinant 
adenovirus vaccines expressing NP have been previously evaluated in both the presence 
and absence of maternal antibodies in young pigs.
34,35
  Adenovirus-based NP vaccination 
alone decreased nasal shedding on days 1, 4, and 5 post-homosubtypic challenge when 
compared to non-vaccinated controls with no significant differences in gross lung lesions 
observed between the two groups.
35
  A similar decrease in viral load with no differences 
in lung lesions was also observed in this study, but the challenge strain used here was 
heterosubtypic to the vaccine gene.   
The mechanisms regarding NP-specific protection following heterosubtypic 
challenge have yet to be fully elucidated.  Initially, it was shown that a specific CD8+ 
cytotoxic T lymphocyte (CTL) immune response was needed for heterosubtypic 
protection,
24,36
 and eventually a role for cytokine-secreting CD4+ T cells was also 
demonstrated.
25
  B cell-deficient mice primed with influenza virus develop enhanced 
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immunity following heterosubtypic challenge but  this protection was no longer observed 
when the CTL population was depleted.
23
  However, other studies have questioned the 
necessity of a CTL response for protection following NP vaccination and suggest a 
possible role for NP-specific antibodies.
1,6
  A recent study demonstrated that antibody-
deficient, T cell-competent mice were not protected against influenza challenge following 
NP vaccination, but these mice were protected after passive transfer of NP-specific 
antibody serum.
3
  This protective role for anti-NP antibodies is in contrast with a 
previous study that demonstrated that transfer of anti-NP monoclonal antibody to scid 
mice (B and T cell-deficient) resulted in no protection from influenza challenge.
10
  
Together, these studies indicate that both functional B and T cells are required for 
efficient protection against heterosubtypic influenza.  In the current study, we 
demonstrate both robust B and T cell responses following NP vaccination via NP-specific 
ELISA and IFN-γ ELISPOT, respectively.  Again, placebo vaccinated pigs did not 
seroconvert to NP, demonstrating the safety of this vaccine platform.  The IFN-γ CMI 
response was specific for both H3N2 and pH1N1 influenza viruses.  Further, stimulation 
of PBMCs with NP RP resulted in an increase of IFN-γ secreting cells.  This increase 
was not observed when PBMC collected from the PRRSV M RP group (placebo) were 
stimulated with NP RP, indicating that the increase in IFN-γ secreting cells was antigen-
specific (NP) and not induced non-specifically by the alphavirus replicon platform.  IFN-
γ is the main cytokine released by CD8 effector T cells, and is also released by TH1 CD4 
T cells.  Subsequent studies and flow analysis in our lab have shown that the majority of 
IFN-γ produced in pigs following RP vaccination is from the CD4+CD8+ T cell subset, 
and to a smaller percentage, CD4+CD8- and CD4-CD8+ subsets (data not shown).  The 
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CD4+CD8+ subset is comprised of memory T cells, and has been shown to have a 5-10 
fold higher frequency of IFN-γ producing cells than the other two lymphocyte 
populations in pigs.
38
  Thus, this double positive T cell subset may play an important role 
in protecting pigs against heterosubtypic influenza infection. 
In summary, the studies presented here demonstrate that the alphavirus replicon 
system can be used to produce RP vaccines that induce specific humoral and CMI 
responses against emerging viral diseases, and can also be utilized for the further 
development of influenza vaccines that offer heterosubtypic protection. 
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Table 1. Study 1 hemagglutination inhibition (HI) geometric mean reciprocal titers and average daily  
gain (ADG) ± standard error of the mean (SEM)*. 
Group HI Titers 
    
14 dpb1 
 
26 dpb 
 
ADG pH1N1  H1N1 992 Pfizer XP-012   pH1N1   
Placebo 0.0 ± 0.0a 0.0 ± 0.0a 0.0 ± 0.0a 
 
0.0 ± 0.0a 
 
1.8 ± 0.2a 
HA RP 121.3 ± 19.6b 60.6 ± 9.8b 34.8 ± 11.0b   91.9 ± 24.0b   2.5 ± 0.3a 
*Values within a column not connected by the same superscript letter are significantly different (p<0.05). 
1dpb: days post-booster vaccination 
2Field SIV strain isolated in 1999 at Iowa State University Veterinary Diagnostic Lab (H1N1 γ-cluster) 
 
 
 
Table 2. Study 1 mean TCID50/ml log10 virus titers of nasal swabs (NS), gross and histopathological lung 
scores ± standard error of the mean (SEM)*. 
Group Log10 Virus Titers   Gross Lung 
 Scores (%) 
Histopathological 
 Lung Scores (0-3) NS 4 dpc1 NS 5 dpc   
Placebo 3.1 ± 0.2
a 3.1 ± 0.2a 
 
15.6 ± 5.4a 1.8 ± 0.1a 
HA RP 0.0 ± 0.0
b 0.0 ± 0.0b   3.6 ± 3.1
a 1.0 ± 0.0b 
*Values within a column not connected by the same superscript letter are significantly different (p<0.05). 
1dpc: days post-challenge 
 
 
 
Table 3. Study 2 mean NP ELISA S/P values ± standard error of the mean (SEM). Values  
≤0.67 are considered positive*. 
Group Multiscreen NP ELISA 
Pre-Vac 0 dpb1 8 dpb 21 dpb 
Placebo 0.82 ± 0.03
a 1.01 ± 0.02a 0.93 ± 0.02a 0.90 ± 0.02a 
NP RP 0.85 ± 0.02
a 0.55 ± 0.03b 0.17 ± 0.02b 0.18 ± 0.01b 
*Values within a column not connected by the same superscript letter are significantly different (p<0.05). 
1dpb: days post-booster vaccination 
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        Table 4. Study 2 mean IFN-γ secreting cells per 1x106 PBMC ± standard error of the mean (SEM)*. 
Group Day of Boost   Day of Challenge 
H3N21 pH1N1   H3N2 pH1N1 NP RP 
Placebo 23.3 ± 8.1a 19.0 ± 8.5a 
 
45.5 ± 10.6a 39.3 ± 11.0a 26.0 ± 9.0a 
NP RP 61.5 ± 9.6b 77.5 ± 14.2b   153.5 ± 51.5
b 189.8 ± 62.7b 126.0 ± 43.4b 
       *Values within a column not connected by the same superscript letter are significantly different (p<0.05). 
             1Stimulating antigen used in ELISPOT assay 
 
 
        Table 5. Study 2 mean TCID50/ml log10 virus titers of nasal swabs (NS) and  
        bronchoalveolar lavage fluid (BALF) samples ± standard error of the mean (SEM)*. 
Group Log10 Virus Titers 
NS 3 dpc1 NS 4 dpc NS 5 dpc BALF 
Placebo 4.2 ± 0.3
a 4.7 ± 0.1a 4.4 ± 0.2a 3.9 ± 0.5a 
NP RP 2.8 ± 0.4
b 4.1 ± 0.1b 3.3 ± 0.3b 1.6 ± 0.6b 
        *Values within a column not connected by the same superscript letter are  
          significantly different (p<0.05). 
  1dpc: days post-challenge
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CHAPTER 6. GENERAL CONCLUSIONS 
 The results presented in this dissertation support the conclusion that alphavirus-
based replicon particle (RP) vaccines are immunogenic, efficacious, and safe for use in 
swine.  Replicon particle vaccines have been evaluated extensively in both the human and 
veterinary fields; however, no replicon-based vaccine has been approved by a 
government regulatory agency to date, although several human candidate vaccines have 
been successfully evaluated in preclinical trials.  This is the first report of a formal RP 
vaccine safety study in a veterinary species.  When the RP vaccine was administered to 
pigs at high doses (200X efficacious dose) there was no detectable shed or spread of the 
vaccine from vaccinated animals to non-vaccinated cohorts. Additionally, no virulent 
virus was detected in any of the tissues samples, indicating a lack of reversion to 
virulence.  These results provide the necessary evidence that RP are safe to use as 
veterinary vaccines and pose minimal risk to animals, humans, or the environment. 
 In addition to demonstrating safety, these studies show that RP vaccines are 
highly immunogenic in swine.  Replicon particle vaccines expressing the hemagglutinin 
(HA) gene from both H3N2 and pandemic H1N1 (pH1N1) influenza strains resulted in 
specific humoral and cell-mediated immune responses.  Following homologous influenza 
challenge, pigs were completely protected against nasal shedding and exhibited reduced 
pulmonary pathology.  In addition, replicon-based vaccines increased the average daily 
gain of vaccinated pigs following influenza challenge, resulting in an increase in the 
economic value of vaccinated animals.  This research also demonstrates the speed with 
which RP vaccines can be produced in response to emerging diseases.  When the pH1N1 
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influenza virus was first reported in the human population, we were able to produce a 
replicon-based vaccine in two months.  Because the viral isolate is not required for 
vaccine production but only a protective gene sequence, production can occur more 
rapidly than for traditional vaccines.  The quick response demonstrated in this study 
could someday be implemented to produce vaccines against foreign or emerging diseases 
(i.e. foot-and-mouth disease virus).  
 Influenza viruses are constantly evolving, and currently many different subtypes 
and clusters co-circulate among the U.S. swine population.
8-10
  There is little antigenic 
cross-reactivity between isolates from these different subtypes and clusters.
1-3,8
  Thus, 
broadly-protective vaccines must either be multivalent or contain antigens that are 
immunogenic and conserved among all influenza strains.  As discussed in Chapter 2, 
multivalent RP vaccines have been shown to be immunogenic and efficacious against 
multiple pathogens.
6,7
  Thus, the RP technology can be utilized to produce a multivalent 
vaccine that expresses protective antigens from multiple relevant SIV strains.  The other 
approach for a broadly-protective SIV vaccine is to focus the immune response against a 
conserved antigen.  This approach was evaluated in Chapter 5 by administering a NP RP 
vaccine followed by a heterologous challenge with pH1N1.  The NP RP vaccine was 
highly immunogenic and induced both humoral and cell-mediated responses, and 
following heterologous pH1N1 challenge, NP RP vaccinated animals demonstrated 
reduced nasal shedding.  These results indicate that, although not as efficacious as 
homologous HA RP vaccination, NP RP vaccines are able to decrease viral load and may 
therefore be an important component of a universal influenza vaccine.  Such vaccines 
could play an important role in reducing future outbreaks of influenza in pigs from non-
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vaccine matched strains.  Vaccines capable of protecting against new strains are also 
important for reducing the zoonotic risk of swine influenza viruses. 
 These studies demonstrate that alphavirus-based RP are good candidates for swine 
vaccines.  However, swine RP vaccine research is still in its infancy with many questions 
or hypotheses that remain to be tested.  First, can an efficacious multivalent SIV RP 
vaccine be developed that offers protection against multiple subtypes and clusters?  
Based on results from previous studies, multivalent RP vaccines have been shown to be 
as effective as the monovalent components of such vaccines.
4-6
  Therefore, there is a 
reasonable expectation that such a multivalent SIV RP will provide comparable levels of 
protection against all strains as the monovalent H3N2 HA RP vaccine.  The alphavirus 
vector can also be easily manipulated to allow several genes to be inserted on a single 
replicon RNA, thus simplifying vaccine production and reducing production costs.   
 The results presented in Chapter 5 indicate that NP RP vaccination reduces the 
level of virus shedding.  How can these promising results be further expanded to develop 
a more efficacious broadly-reactive SIV vaccine?  Other studies have demonstrated 
broadly-protective immune responses utilizing a novel prime-boost strategy of an HA 
adenovirus-vectored vaccine followed by an inactivated influenza vaccine.
11
  
Additionally, an adenovirus vector vaccine expressing HA and NP, when used in a 
prime-boost regimen with an inactivated vaccine, was able to protect young pigs in the 
presence of maternal antibody.
12
  Thus, it is conceivable that by developing an RP 
vaccine expressing both NP and HA that even broader protection could be achieved, 
especially when used in conjunction with novel prime-boost strategies.  An SIV RP 
vaccine that is able to induce broadly-protective immunity and perhaps even provide 
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protection in the presence of maternal antibodies should be further evaluated.  Such a 
vaccine would be very beneficial to the swine industry and would represent a proactive 
approach to preventing further influenza outbreaks. 
 Finally, since the studies presented here demonstrate that RP vaccination of swine 
is safe and efficacious and due to the relative resistance to antivector immunity, RP 
vaccines against other swine pathogens should be considered.  As described in chapter 4, 
RP vaccines are not shed or spread and do not revert to virulence.  This is a tremendous 
benefit when compared to traditional modified live vaccines.  Also, other studies have 
already demonstrated that animals can be immunized multiple times with the same RP 
vaccine or with a different RP vaccine with no effect on the host immune response to 
booster immunizations.
7
  Protective genes from multiple pathogens can also be included 
on one replicon RNA, thereby decreasing the number of injections required.  Therefore, 
multivalent RP vaccines should be further developed for SIV and other important swine 
pathogens.   
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